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Abstract
Genomic epidemiology of Clostridium difficile colonization and transmission in an intensive
care unit cohort
by
Brianne Ciferri, MPH
Advisor: C. Mary Schooling, PhD
Introduction: Clostridiodes difficile (C. difficile) is a leading cause of healthcare associated
infections (HAI) in the United States and responsible for an estimated incidence of 223,900 cases
and 12,800 deaths per year1,2. C. difficile can cause gastrointestinal illness with symptoms
ranging from mild diarrheal illness to a life-threatening condition. C. difficile is an opportunistic
pathogen in which spores can live in an undisturbed dormant state within the intestinal tract and
become active in the presence of favorable conditions. Conditions suitable to C. difficile
proliferation occur when the gut microbiome is in a state of imbalance, usually as a result of
treatment with oral antibiotics, chemotherapy, or illness1,7,8.
The major predictors for developing a C.difficle infection (CDI) include exposure to a
contaminated environment or infectious person and disruption of microbiota. The individuals
most likely to experience illness caused by C. difficile are those with pre-existing health
complications, with infection resulting in a further health decline among individuals already ill.
Given that patients admitted to intensive care units (ICU) are often in a declined state of health
and have many of the predictors associated with CDI, this population is at a greater risk for
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developing infection. In this study I sought to explore the relationship between ICU patients and
CDI by examining demographic, clinical, and genomic data.

Methods: Stool samples were collected from two sources over a four-year period; ICU patients
and positive CDI case patients. The specimens collected from ICU patients included both
positive CDI patients and non-infected patients. The specimens collected from patients who
tested positive for CDI and classified as cases, were collected from the clinical laboratory.
Patients who did not test positive for CDI in the 4-year study window were either matched to
case patients or were selected randomly for screening to determine the rate of asymptomatic
carriers within the ICU. We sequenced the isolates from the patients identified as carriers and the
cases using PacBio long-read sequencing technology. Following genome assembly, open-source
Pathogen Sequencing Phylogenomic Outbreak Toolkit (PathoSPOT) was used to compare the
nucleotide differences to determine the presence of transmissions based on clonal relation which
is defined as being <4 single nucleotide variances between genomes. After we identified groups
of patients involved in transmission clusters, and the possible contribution of asymptomatic
carriers, I examined hospital admission history to determine patient overlap and explore possible
routes of transmission or common unit reservoirs. I also examined the proportion of recurrent
CDI to determine if multiple CDIs were the result of an incomplete decolonization or the result
of a new infection.

Results: I identified an 8.0-8.1% carrier rate within the matched and random controls when
comparing the case, non-infected, and carrier patients. I identified that case patients were
significantly more likely to have had more prolonged contact with the hospital environment
compared to non-infected patients.
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There were 40 transmission clusters identified, 12 of which included asymptomatic carriers, that
ranged in samples collected days to years apart. I next examined hospital admission history to
identify common unit overlaps and observed 1 unit which was significantly associated with
transmission cluster patients visiting that unit prior to CDI. To further examine the possibility of
reservoir units, with the collaboration of the research team we sought to determine if there were
clusters of units associated with transmission rather than a single unit given that patients often
visit more than 1 unit during a hospital admission. We performed a permutation analysis to
identify groups of units that patients commonly transfer between. We identified a total of 10
significant unit clusters, and observed a significant association between CDI patients who were
admitted to the surgical unit cluster and a higher likelihood of being in a transmission cluster
compared to CDI patients not in a transmission cluster. We compared these units with the overall
rate of reported CDI cases within the hospital and observed that the units significantly associated
with a transmission cluster were not the units with the highest rates of CDI. Lastly, I examined
CDI patients who had more than 1 infection and observed that 85.5% of the recurrent infections
were not related.

Discussion: The data observed in each step of the analysis suggests environmental persistence is
the main driver of CDI within the examined cohort. I first identified that case patients had
significantly higher levels of hospital exposure compared to non-infected patients. This suggests
that prior to any genomic analysis, there were already indications that increased exposure to the
hospital environment was more associated with testing positive for CDI compared to noninfected patients. After we performed genomic sequencing and identified the 40 transmission
cluster, we joined the genomic data with hospital admission data and observed that the majority
of patients in transmission clusters (77.5%) did not overlap in the same units at the same time(?).
iii

This suggests that patients likely encountered the bacteria while visiting the same unit at
different times, rather than direct transmission from patient encounters. We identified that a
cluster of units associated with surgical patients were more associated with patients involved in a
transmission compared to patients not involved in a transmission. These findings suggest that the
pre- and post- surgical units may have higher levels of environmental contamination given that
clonal isolates were observed in patients who were admitted to these units months, and in some
cases years, apart. Additionally, given that the units in the surgical cluster were not the units with
the highest reported overall incidence of CDI, suggests that these units are specifically associated
with transmissions, and not artificially inflated due to a heightened overall CDI rate. Lastly, the
observation that recurrent cases are more often associated with new infection rather than a
persistent infection, further supports my hypothesis that environmental contamination is the
driving factor in many transmission cases of CDI. This study has yielded findings to further our
clinical and scientific understanding of how C. difficile spreads within the healthcare
environment and the drivers of transmission. I observed transmission clusters containing patients
with clonally related strains with unit overlap spanning as little as 1 week, to as much as 4-years
apart. Additionally, the data suggests that the unit overlap was not in the units in which the CDI
was diagnosed. These results strongly suggest that the source of transmission is environmental
exposure to units visited earlier in the hospital admission prior to having a positive CDI test
result.
The standard protocol following a CDI diagnosis is cleaning and containment, which is
seemingly effective given that we did not observe patient overlap in the units where patients
tested positive. Consequently, this suggests that direct patient-to-patient transmission does not
play a major role in transmission, and that environmental persistence caused by ineffective
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cleaning of units visited prior to diagnosis is driving in transmission. This study has provided
new data to inform evidence-based infection control guidelines to reduce the incidence and
prevalence of CDI in the hospital environment.
Conclusion: Genomic sequencing technology was the critical method used in this study, and is a
valuable tool in not only outbreak tracking but understanding how diseases move through an
environment and population. Genomic technology provides a level of precision surveillance
without which we would be oblivious to what is a coincidental case of same strain infections
versus a true outbreak. This technology allowed us to identify environmental persistence as the
driver of transmission within the patient population. Using genomics also enabled observation of
transmission clusters that spanned multiple units, patients, and years, which would otherwise
have remained undetected. We were then able to merge this transmission cluster data with
patient admission history and identify the presence of reservoir units. The methods utilized in
this study should be applied to other healthcare associated infections to increase our
understanding of persistence in the presence of effective containment and cleaning protocols.
The future of infection control must focus on expanding strategies beyond defensive measures in
response to infection, and must apply proactive efforts to mitigate the root of transmission. With
the implementation of evidence-based strategies we can work towards reducing the burden of C.
difficile and ultimately eliminate the associated morbidity and mortality caused by HAI.
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Chapter 1: Introduction
Introduction
Clostridiodes difficile (C. difficile) is a leading cause of healthcare associated infections (HAI) in
the United States and responsible for an estimated incidence of 223,900 cases and 12,800 deaths
per year1,2. The consequences of this endemic disease have caused significant morbidity and
mortality and resulted in an economic burden of ~5 billion dollars in direct health care
expenditure per year3–5.
C. difficile is an opportunistic pathogen that causes gastrointestinal illness when presented with a
favorable environment. The gut microbiome is a dynamic environment located within the
digestive tract and composed of microorganisms responsible for controlling healthy digestion
and aspects of the immune system6. An imbalance microbiome can lead to a variety of different
health complications6. Conditions suitable to C. difficile proliferation occur when the gut
microbiome is in a state of imbalance, usually as a result of treatment with oral antibiotics or
illness1,7,8. The individuals most likely to experience illness caused by C. difficile are those with
pre-existing health complications, with infection resulting in a further health decline among
individuals already ill. Additionally, C. difficile are uniquely hardy bacteria that can persist in the
environment for months if proper cleaning protocols are not followed. Major predictors for
developing CDI include exposure from a contaminated environment, antibiotic usage, or direct
transmission from an infectious person (Figure 1). In order to reduce incidence, interventions
need to focus on the chain of transmission and environmental persistence to identify risk before
the disease can be transmitted.
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There is a gap in the current knowledge of understanding transmission and environmental
dynamics on the genomic level. In the past, studies examining C. difficile infection (CDI) events
and transmissions classify outbreaks based on the same strain type, however studies have shown
that a more detailed examination of the genomic attributes is required to accurately identify
transmission9–11. More detail on the genome beyond strain type can yield the distinct distance
between nucleotides and allow us to genetically identify a direct transmission10. Without this
comprehensive information, cases may be falsely classified as a transmission solely because of
matching strain, a likely occurrence particularly if both cases are infected with the most common
strain. Using whole genome sequencing (WGS) allows us to genetically determine the
phylogenetic relationship between isolates and provide conclusive evidence of transmission
events10,12. WGS can also provide information on strain variants and subgroups, and may
indicate future characteristics of the disease allowing policymakers to develop more clinically
effective evidence-based prevention strategies.

Background & public health significance
HAIs have become a global endemic with a projected burden of 1 in every 31 hospitalized
patients developing a HAI resulting in approximately 1.7 million infections and 99,000
associated deaths in the United States each year13,14. C. difficile is responsible for more than
20% of hospital onset diarrheal illness, making C.diffiile a high priority pathogen13. C. difficile
infection (CDI) outcome is determined by both patient risk factors, such as receiving antibiotics,
as well as being exposed to the bacteria7,15. Patients admitted to an Intensive Care Unit (ICU)
often have increased length of stay which may include higher rates of antibiotic usage, increased
likelihood for physical exposure to pathogens, and higher rates of immunocompromised
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individuals; features which generate a highly vulnerable host population14,16,17. The unique
environmental persistence of the bacteria coupled with the nature of a hospital which houses a
supply of susceptible hosts, creates a challenging infection control paradigm.
The economic burden caused by endemic CDI has cost the healthcare industry billions of dollars
in C. difficile related expenditures amounted to over 1 billion dollars spent each year17–19.
Researchers have continuously linked HAIs with progressively higher prevalence of antibiotic
resistant pathogens which causes increased rates of negative health effects and a growing threat
to public health18–21. Infection control measures have been in place for over 3 decades to control
CDI and other HAI’s, however rates remain endemic across a variety of healthcare facilities
including acute and long-term7,15. WGS is a critical tool in combating the incidence of HAIs, and
can provide the necessary information to trace possible routes of transmission and break the
chain of infection.

Overview of study
To identify the burden of CDI and carriers in the hospital environment I examined a high risk
patient cohort, which was defined as ICU patients due to their increased risk of CDI. The patients
were followed longitudinally to monitor subsequent disease onset and split into two control
groups and one case group. Following colonization identification through screening, I explored
genomic variance and transmission of carriers and symptomatic cases. Using a multimethod
approach allowed for the examination of disease incidence and transmission dynamics.
Exploring transmission dynamics on the genetic level revealed multi-year outbreaks, the
contribution of asymptomatic carriers, and potential environmental reservoirs within the hospital.
Investigating the interaction between host, environment, and pathogen through analysis of a
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robust clinical cohort with extensive genomic sequencing can advance public health
development of evidence based prevention of C. difficile and may act as future guidance for
understanding and ultimately preventing further burden of HAIs. This study was made possible
by the efforts of a large mutidisciplinary team including biostatisticians, laboratory technicians,
and bioinformaticians. Throuhgout this thesis I will refer to the individual work I contributed,
and what was completed with the assistance of the other members of this research study.

Aims & hypothesis
This study sought to explore the transmission dynamics on the epidemiological and genomic
level between C. difficile infected patients, asymptomatic carriers and non-infected patients. This
analysis was conducted through examination of a unique longitudinal patient cohort at a large
urban hospital. I identified the overall colonization rate and described the variation between
asymptomatic and symptomatic disease expression relating to demographic and clinical
predictors. Genomic sequencing was performed on samples from identified asymptomatic
carriers and symptomatic cases. Using the sequencing data I determined the overall distribution
of strain types within symptomatic and asymptomatic patients and explored possible correlations
between disease outcome and strain type. I also examined the strain diversity among cases found
to be part of a transmission to determine if certain strains were associated with higher infectivity.
Lastly, we determined the genetic relatedness based on nucleotide variance between genomes to
identify transmission clusters, and performed an enrichment analysis to identify potential seed
units within the hospital. To answer these questions, I applied a multi-method approach using
experimental, statistical, genomic, and bioinformatic analysis.
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Aim 1 Identification, description, and sequencing of asymptomatic carriers, and
description of study cohort
Establish the prevalence of asymptomatic C. difficile carriage and determine
epidemiological and clinical correlations between asymptomatic carrier patients,
symptomatic case patients, and non-infected patients
Aim 1.1 Select and describe the study cohort
Identify and select patients to be included as cases, matched controls and random controls.
Describe the demographic and clinical make-up of each group.
Aim 1.2 Screen for asymptomatic carriage through laboratory optimization of qPCR assay and
sequence the genome
Stool samples collected from patients in the ICU were selected for screening using a stratified
random sampling design to increase generalizability and address possible selection bias. DNA
extraction and real-time quantitative PCR-based assays (qPCR) were performed and
experimentally optimized to detect presence of the C. difficile related tcdB gene and to
distinguish the total bacterial load of chromosomal DNA. Assays were performed on
longitudinal samples collected from the study population within the hospital, and I identified a
threshold for evaluating the disease-causing tcdB gene. The genomes were sequenced of the
isolates identified as being colonized with C. difficile using PacBio long read sequencing (LRS)
technology. The results of this section determined the overall asymptomatic carrier prevalence
within the selected screening cohort.
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Aim 1.3 Distinguish characteristics and predictors of asymptomatic carriers compared to
complete study cohort
Following identification of asymptomatic carriers, I compared demographic and clinical factors
between carriers, symptomatic cases, and non infected patients. Trends among these groups were
evaluated using multivariable regression techniques and risk stratification models.
Aim 2 Identify transmission clusters, recurrence, and strain diversity among sequenced
isolates
Aim 2.1 Identify strain diversity
Strains and sub-strains were identified for each isolate using multi-locus sequence typing. The
strain diversity between asymptomatic carriers and symptomatic cases was examined to
determine if there were strains associated with disease outcome (case/carrier). Strain type was
also compared between isolates that were or were not involved in a transmission cluster to
identify strains that may exhibit increased infectivity.
Aim 2.2 Describe transmission clusters
Following genome assembly, the isolates were grouped into transmission clusters. Genomes
from isolates with asymptomatic colonization were included in the transmission cluster analysis.
Additionally, I examined the nucleotide distance between isolates from the same patient to
determine if recurrent positive tests were a result of reinfection or inadequate decolonization
from the initial infection.

6

Aim 3 Enrichment analysis within transmission clusters to identify potential transmission
reservoirs within the hospital
Aim 3.1 Examine unit admissions 6 months before CDI to identify potential reservoir units
Within the patients involved in a transmission cluster I explored the hospital units they were
admitted to 6 months prior to the CDI positive test date. I used hours within the unit as the
exposure variable with the outcome as being involved in a transmission. I identified 2 units that
were statistically significant at the .05 level using logistic regression. The exposure variable
examined was hours within the unit, with the outcome variable involvement in a transmission
cluster. Permutation analysis was then utilized to validate our findings. This section can provide
evidence that CDI based infection control should target units with higher rates of transmission in
order to combat the root of the infections rather than the current protocol which targets the units
in which the infection surfaced.
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Figure 1 Directed acyclic graph
Directed acyclic graph (DAG) demonstrating a conceptual framework associated with
asymptomatic host colonization as a source of endemic C. difficile infections in the hospital
environment. Predictors are shown on the top, potential outcomes are shown on the bottom.
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Chapter 2: Literature Review
Section 1: Biology of Clostridium difficile
Microbiology
C. difficile is a gram-positive anaerobic spore forming bacilli, displaying increasing resistance to
a variety of antibiotics

7,18,22,23

. C difficile is an opportunistic pathogen which can cause

significant overgrowth in gut microbiota during a state of disruption, a common side effect of
illness and antibiotic therapy24. The bacterium was first reported in the gut flora of healthy
infants in 1935 and named Bacillus difficilis describing its difficult nature to culture and isolate
8,25,26

. At this time, it was described as “actively motile, heavy-bodied rod with elongated

subterminal or nearly terminal spores” and although reported as non-disease causing in infants, it
was found to cause disease in animals8,26,27. The bacteria was renamed to C. difficile in the 1970s
when it was recognized as causing pseudomembranous colitis following antibiotic exposure in
humans, and today is considered an urgent threat within healthcare institutions8,24,25. C. difficile
is a species within the class Clostridia and can be distinguished from other species in this class
for its ability to decarboxylate parahydroxyphenylacetic acid to produce p-cresol, often resulting
in the associated tar-like odor during infection25,27.
C. difficile is transmitted via the fecal-oral route from dormant spores persisting in the
environment or diretly from an infected person1,25,27–29. Spores are resistant to alcohol-based
cleaners and are only killed in the presence of hydrogen peroxide and bleach-based
cleaners18,23,30,31. Spores can persist in the environment for over a year, but it remains unknown
how long the spores may remain in the environment in unaltered conditions18,23,29,30,32. The
9

durable spore is the vehicle protecting the inner vegetative cell which enables the bacterium to
transmit disease, without which it would not survive in the environment. Sporulation occurs in
the event of nutrient depletion and quorum sensing dictated by the Spo0A regulator33,34. Housed
within the spore is the dehydrated core containing the biological mechanisms required to
regenerate metabolic activity such as DNA, tRNA, ribosomes, and enzymes8,33–35. The
dehydration of the core is a key component in the cell’s ability for enzymatic dormancy,
allowing the DNA within the core to bind to protective DNA altering small acid-soluble proteins
which enable the spore to be resistant to damage caused by heat, chemicals, and UV36,37. The
core is also protected by an inner membrane which prevents DNA damaging elements from
entering the cell, which is further encased in a peptidoglycan germ cell wall which transitions to
the outer cellular wall during germination33,34. The final surrounding layers are a spore coat
which consists of proteins to protect the cell from chemicals, enzymes and biocides, and a
multilayered protein exosporium, both of which disband during germination33,36,38. Differences in
the morphology within this final outer layer have been described based on strain type
demonstrating that spores that lack this layer have a reduced resistance to lysozyme, ethanol, and
heat33,36.
Once spores are ingested they adhere to the large intestine epithelial lining and/or the lining of
the colon36. Germination triggering metabolic activity is dependent on the presence of favorable
biological signals and abundance of specific biles within the gastrointestinal tract34,39,40 (Figure
2). It was identified early on that the primary bile acid taurocholate produced from the liver
triggers the germination process when binding to the CspC receptor, however Sorg et al.
uncovered that the bile salt cholate and glycholate can also promote germination40,41. Secondary
bile salts produced in the colon are regulatory compounds which hinder receptor binding and
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block the signal to germinate42,43. Microbiota species in healthy individuals regulate the primary
bile salts triggering germination through dehydroxylation to produce the inhibitory secondary
bile acids deoxycholate and lithocholate34,36,39,42–44. In the presence of a disrupted or unbalanced
microflora, such as from exposure to a broad spectrum antibiotic, these regulating species are
absent leading to a higher abundance of unregulated germinates and receptors triggering
germination42,45,46. Once germination occurs, the outer two layers (spore coat and exosporium)
dissolve leaving behind the peptidoglycan layer27,33,39. This layer becomes the outer cellular wall
and is ready to initiate vegetative cellular growth27,33,39.
C. difficile results in symptomatic disease expression when the bacteria produce cytotoxin A
(TcdA) and/or cytotoxin B (TcdB), both of which have a high molecular weight27,34. These genes
are encoded in the pathogenicity locus within the bacterial genome which also encodes 3 proteins
identified as regulators for toxin production and secretion (TcdR, TcdE and TcdC)47,48. The
toxins act by disrupting the actin cytoskeleton of the intestinal epithelial cells resulting in
translocation of commensal bacteria and inundation of inflammatory cells chemokine and
cytokine48–51. Epithelial cell death, increased neutrophil abundance, and fluid secretions can also
be caused by toxin secretion27. The resulting inflammatory response causes a comprehensive
range of host cellular response including severe diarrhea, colitis, and tissue necrosis8,25,27.
Following active symptomatic infection spores are released back into the environment thereby
continuing the infectivity cycle.

Epidemiology
C. difficile is classified by strain type which is identified using a polymerase chain reaction
(PCR) to detect the ribotype (RT), and multilocus sequence type (MLST) (Figure 3) . Strain
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typing using RT detection is a PCR based method which directs primers at conserved regions of
the ribosomal genes (16S rRNA & 23S rRNA) and then amplifies the intergenic spacer between
the regions8,52,53. The results of this PCR identify the strain type by comparing the amplification
results with reference strains. MLST works by measuring a set of housekeeping genes (loci) and
compared to a reference genome to identify the strain based on the allelic profile12,52,54,55.
C. difficile has diverse strain types divided into 5 global clades which exhibit varying levels of
virulence, however there are several highly clonal strains circulating in healthcare
institutions47,56–58 (Figure 4). Although the existence of 5 Clades is the primary consensus in the
current literature, some studies have reported the existence of 2 more possible Clades. The first
lineage, classified as Clade 6, contains only one strain (RT131) and was designated a novel
lineage however some studies argue it is a highly divergent hybrid of Clade 1 and Clade 2 and
not an actual new Clade9,59,60. The second novel lineage, designated C-I, contains a highly
divergent non-toxigenic strain which may possibly be a new lineage of C. difficile, however
conclusive evidence and consensus is currently lacking35,58,61.
Clade 1 includes over 100 toxigenic and non-toxigen strains creating a highly heterogeneous
cluster8,57. Clinically relevant strains in Clade 1 include RT002, RT014, RT018, with RT002
exhibiting increased prevalence in Middle Eastern countries and RT018 driving CDI outbreaks in
South Korea and Italy demonstrating high levels of fluoroquinolone and clindamycin resistance
57–59,62

. Clade 2, the clade which contains the hypervirulant RT027, also includes clinically

significant RT244 and RT17663–65. Clade 2 is globally endemic with RT027 being the highest
reported strain in North America and the UK63–65. Clade 3, the least studied clade in the current
literature, contains the European RT023 which previously was reported as non-hypervirulent,
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however new studies have emerged showing that disease outcome of RT023 is similar to the
hypervirulent RTs in clade 235,57.
Clade 4 contains RT017 which has shown increased resistance to clindamycin and
fluoroquinolones and has been the source of outbreaks in Europe, Argentina, and North America
in the 1990s. Despite the lack of toxin A and binary toxins produced in RT017, the strain has
been the source of outbreaks for over 30 years and was recently declared the primary strain of
CDI infections throughout Asia

62,66,67

. Clade 5 includes diverse strain types many of which are

zoonotic in origin and circulate in humans, animals, and food sources35,68. Clade 5 is more often
identified in in Asian and Middle Eastern countries35,68,

69

. RTs in this clade include RT033,

RT045, RT066, RT078, RT126, RT127, RT237, RT280, RT281, and RT288. RT078 has
demonstrated higher divergences from other strains in Clade 5 and is primarily associated with
zoonotic transmission, especially within livestock35,61,69.
Virulence and incidence of RT027/NAP1/ST1
Included in Clade 2, and endemic throughout healthcare institutions is strain-type 1
(NAP1/ST1/RT027) which is responsible for >30% of CDIs and identified as one of the most
prevalent multilocus sequence types (MLST)63–65.

NAP1 was identified as an endemic

hypervirulent strain in the early 2000s causing outbreaks in Canada, the United States, Europe,
and Asia. Two fluoroquinolone-resistant (FQR1 and FQR2) lineages diverged and spread in the
US with FQR2 responsible for a greater number of infections70. The increase in CDI incidence
and mortality from 1993 to 2003 is attributed to the introduction of the NAP1 strain4,63,71–73.
This strain is classified as hypervirulent compared to other strains due to a 15-20 fold increase in
toxin production and is highly resistant to fluoroquinolone antibiotics which was not previously
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seen in the bacteria4,25,74. Additionally, NAP1 demonstrated hypervirulence due to a mutation
suppressing a negative gene regulator which increased the release of toxins causing higher rates
of sporulation63,65,75,76.
Reports identified a reduction from 55% to 21% during 2007 to 2011 in the incidence of NAP1
in England following the decrease in fluoroquinolone prescribing, leading to a significant
reduction of morbidity and mortality caused by NAP1

77,78

. The endemic rate of NAP1 can

hinder attempts by infection control to track outbreaks and may lead to missed transmission
events or inaccurate classification of transmission without consideration to genomic
relatedness24,30,79. Since 2011 there has been a steady reduction in the incidence of NAP1 across
the US Veterans Health Administration (VHA) with a statistically significant reduction rate in 4
of the 9 US Census Bureau regions80. It is unclear if this reduction reflects the increase in strain
variance creating a more balanced strain distribution, or adoption of antibiotic stewardship
practices.
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Figure 2 Biological infectivity cycle
Description of the biological process leading to CDI infection. The patient is first exposed to the
bacteria by contact with a contaminated individual or spores in the environment. If the patient
ingests these spores the bacteria may adhere to the lining of the intestinal wall. In the event of a
disrupted microbiome, such as from exposure to antibiotics, chemotherapy, or underlying illness,
the spore can shed the protective coat which allows it to remain viable in both the external and
internal environment. After the coat is shed and the germination process begins, the DNA
becomes rehydrated and can begin toxic production leading to infectious illness. The primary
symptom of CDI is continuous diarrhea which is the mechanism carrying the bacteria into the
environment. This process can lead to further patient exposure and subsequent infection, thus
contributing to transmission and environmental persistence.
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Figure 3 Strain typing methods
Two methods used to classify the strain type of C. difficile are Multilocus sequencing typing
(MLST), and ribotyping. MLST is a molecular biology technique that uses reference genomes to
compare multiple loci of housekeeping genes found within the core genmore. Ribotyping
involves using a PCR technique to cleave the DNA using a restriction enzyme at a specific
nucleotide sequence. Following the PCR, gel electrophoresis is performed using a membrane
enriched with hybridized 16S or 23S rRNA probes which are used to detect the specific sized
fragments.

16

Figure 1 Clade description
C.difficle is classified into 5 separate Clades which each exhibit their own unique characteristics.
The Clades are defined though genetic relatedness of strains, therefore many strains within the
Clades are similar. Some Clades, such as Clade 2, are studied more in depth due to the higher
proportion of disease causing strains within the Clade. This figure provides examples of
significant strains in each Clade and why those strains are significant.
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Section 2: Infection, risk, and clinical presentation
Morbidity and mortality
The CDC reported in the 2019 Antibiotic Resistance Threats Report >2.8 million antibioticresistant infections resulting in >35,000 deaths per year. This includes 223,900 cases of CDI
resulting in 12,800 deaths in a single year in the US2. C. difficile is predominantly classified as a
nosocomial infection resulting in significant morbidity and mortality, particularly in those
already suffering from serious illness. In recent years community acquired CDI has been
increasing with an estimated 51.9 cases per 100,000 persons8,75,81,82. CDI is less common among
children (<18 years old) compared to adults, however pediatric cases are largely reported as
community-acquired rather than hospital-acquired1,73,83,84. Most notably, infants <1 year old are
disproportionately colonized compared to young children >1 year old85–88. CDI is considered an
urgent threat by the CDC and a rising global concern causing significant rates of morbidity and
mortality, with considerable urgency given the increase in community acquired CDI over the
past decade1,8,25,83.

Disease expression: symptomatic illness versus asymptomatic colonization
Clinical symptomatic presentation of CDI is defined as watery diarrhea 10 to 15 times daily,
abdominal cramping, increased heart rate, fever, bloody stool, nausea, dehydration, and loss of
appetite. In the most severe cases, symptoms can cause confusion or disorientation leading to
shock15,25. CDI can present a range of clinical symptom severity from mild illness to life
threatening disease such as pseudomembranous colitis, fulminant colitis, toxic megacolon, bowel
perforation, sepsis, and multiple organ failure. If the infection is cannot be clinically controlled
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and symptoms progress in severity, complications from CDI can damage the intestines and
bowel causing inflammatory conditions such as pseudomembranous colitis and fulminant
colitis8,24,89. Toxic megacolon is also defined as an inflammatory bowel disease but occurs once
the condition reaches life threatening severity causing a potential bowel perforation which can
introduce sepsis and organ failure24,90. There is considerable variation in disease outcome given
the varying characteristics of at-risk patients; however, patients with already serious illness are
most vulnerable to the most serious outcomes of the disease.
In certain individuals C. difficile can be present in the colon without producing clinical
symptoms and causing no harm to the individual carrying the bacteria, possibly due to low toxin
expression and/or low bacteria abundance91–93. Such cases are known as having asymptomatic
colonization, or the person being an asymptomatic carrier. Approximately 3-18% of adults in the
general population are colonized with C. difficile which can increase their risk of developing
symptomatic CDI if the microbiome is disrupted and the bacteria has a chance to proliferate and
cause disease9,11. Spores shed in feces of asymptomatic carriers may act as an additional source
of exposure; however, it is unclear to what extent this contributes to transmission and CDI risk
within the hospital environment30,79. Current literature lacks comprehensive data on infectious
state transitions and the true burden carriers contribute to transmission and contamination91,92.
Previous studies have attempted to define the risk of asymptomatic carriers transmitting CDI or
causing outbreaks. Paquet-Bolduc et al. conducted a unit-wide screening of 114 patients during a
CDI outbreak and determined a 13% carrier prevalence94. Risk factors for asymptomatic
colonization are not as well understood as the risk for developing symptomatic infection.
Additionally, current literature lacks understanding the distinction between risk of colonization
in the community versus in the healthcare setting. CDI research is predominantly focused on
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healthcare-associated cases given this environment produces the most risk and cases of diseases,
however infection within the community remains a possibility as does the risk of colonization.
Colonization within the community is a poorly understood area of C. difficile research, with
many studies lacking representative samples and having low sample size. Many community
based studies have identified clusters of colonized individuals with identical C. difficile strain
types however these are mostly groups of family members, employees or students indicating
local transmission rather than transmission in the community as a whole32,95,96. Galdys et al
conducted a study examining 106 healthy adults in Pittsburgh and found no statistically
significant differences in participant exposures or characteristics between 7 colonized and 99
non-colonized participants, however the low sample size may have may made it difficult to
detect small differences97. Identifying an outbreak of CDI within the community is a difficult
task given that individuals that may have become colonized in the community usually will not
develop symptomatic CDI unless receiving a medical intervention or antibiotic therapy, at which
point the case would then be classified as healthcare associated95,96.
To better understand colonization and thereby begin to define the risk carriers impart for
transmission, CDI should be further explored within the community setting. Prior hospitalization
within 2 months is the most reported risk factor associated with colonization24,94. Use of H2
blockers, proton pump inhibitors, chemotherapy treatment, and cephalosporin are also reported
as risk factors for colonization however given the nature of these risk factors the individual
would likely be exposed to a healthcare facility thereby making these risk factors mediators in
the causal pathway25,50,75. Hospitalization or exposure to a healthcare setting results in high risk
due to the increased likelihood of being exposed to spores shed in the environment by a
symptomatic CDI patient (Figure 5).
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An additional necessity for deepening our understanding of asymptomatic colonization is to
define the risk that carriers pose within the chain of transmission98,99. Multiple studies have
sought to quantify the level of risk posed by carriers transmitting C. difficile by implementing
screening programs on admission to hospital and implementing contact precautions on those
individuals identified as carriers78,93,94,100,101. Lanzas and Dubberke examined the effectiveness of
screening on admission followed by implementing isolation procedures from an agent based
model. They identified that 40-50% of hospital onset CDI would be prevented and 10-20% of
hospital acquired colonization would be prevented. These estimates were determined using a
baseline of community onset infection of 42%102. Although these results indicate a promising
case reduction, the baseline infection rate in the model is not transportable to different
communities or hospital settings. A population based study in Denmark screened patients on
admission to identify carrier status and followed the patients through their hospital admission to
identify other patients potentially exposed to spores shed by the carriers. It was found that 4.6%
of patients exposed to carriers developed CDI compared to 2.6% of patients that developed CDI
who were not exposed to carriers103. These results indicate there may be an association between
CDI and carrier exposure, however the extent of the uncontrolled confounding, the possibility of
over-adjustment, such as adjusting for number of patient transfers, length of stay, and antibiotic
exposure, make interpretation difficult.
Compared to patients who remain colonized without developing CDI, patients who transition
from a colonized state to an infectious state have significantly lower levels of the serum
immunoglobulin (Ig)G which has been shown to be protective against toxin A (TcdA) and toxin
B (TcdB)104–106. Na’amnih et al. conducted a case-control study to further explore the systemic
immune response in relation to CDI disease severity. Sera levels of IgG and IgA antibodies were
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measured and compared to levels of TcdA and TcdB in 50 CDI case patients with either mild or
severe CDI and compared to sera levels of non-CDI controls106. Patients classified as having
mild CDI had significantly higher levels of the IgG antibody (p-value=0.004) compared to
patients with severe CDI (p-value=0.036)106. These findings suggest that the humoral immune
response to CDI may play a greater role in disease severity or progression than the current
literature has described105–107.
Although knowledge is limited in understanding the immune response to CDI in adults, an even
greater knowledge gap exists in understanding the serum response and protective effect IgG may
have among infants. Infants have been shown to be disproportionately colonized with C. difficile
compared to children at an older age32,86,87. Kociolek et al. conducted a prospective cohort study
to determine serological sequelae and better understand colonization among infants. Serial stool
samples were collected from healthy infants aged 1-2 months and again at age 9-12 months87.
Samples were tested for toxigenic and non-toxigenic C. difficile colonization, and underwent
whole genome sequencing. Serum from samples collected at 9-12 months were measured for
IgA, IgG and IgM and compared to presence/levels of tcdA and tcdB, along with antibody titers
compared to tcdB. Of the 32 infants sampled 16 were colonized with toxigenic C. difficile, with
12 of the 16 tcd carriers having been colonized for >1 month. Among the 12 infants who had
been carriers for >1 month, there were significantly higher serum IgA and IgG against tcdA (pvalue=0.02, for both antitoxins) and tcdB (p-value=0.008, IgA; p-value=0.009, IgG) compared to
the infants with no tcd colonization87. These results support the necessity for further examination
of humoral immune response within infants and future studies to determine any lasting protective
effects. It is unknown if this population contributes to community spread87.
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Risk predictors
Predictors of symptomatic disease
The risk for developing CDI is determined by both patient status, such as receiving antibiotics, as
well as exposure to the bacteria. Opportunistic pathogens such as C. difficile take advantage of
an abnormal physiological state such as a weakened immune system or an altered microbiota
resulting from antibiotic exposure to the gut microbiome1,18,25,108. Patients receiving antibiotic
therapy may have an altered or less diverse gut microbiome which can increase susceptibility to
CDI19. Antibiotics eliminate bacteria within the body, and in the case of oral antibiotics the
natural gut flora within the gastrointestinal tract is affected19. Susceptible patients may then be
exposed to C. difficile through the environment (persistence), infected patients, or asymptomatic
carriers23,30. Additional patient risk factors of developing CDI are advanced age; a weakened
immune system, such as from HIV, cancer, recent organ transplant and/or receiving
immunosuppression therapy; recent exposure to a healthcare facility such as hospital or nursing
home; and patients with a history of CDI7,8,24,82,109–112.
Song et al. recently conducted a retrospective case-control study to investigate temporal changes
in hospital acquired CDI risk factors within the past 11 years. 694,849 discharged patients were
examined for CDI status from 3 hospitals in New York City. They identified 6,038 (0.87%)
patients that were diagnosed with CDI with 44% classified as hospital acquired and 56%
community acquired82. Using a 1:4 ratio of cases to controls they examined prior clinical history
such as co-morbidities and medication usage, and overall patient demographics, such as age.
Throughout the 11 year period they identified a decrease in the overall usage of high risk
antibiotics such as broad-spectrum (-1.2%), an increase in the overall administration of
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antibiotics (+3.3%), and an increase in the duration of antibiotic use (+4.4%) for those with
hospital acquired CDI. Also observed was a reduction in the incidence of hospital-acquired CDI
(-0.03%) and an increase in the incidence of community acquired CDI (+0.04%)82. The authors
did not identify a temporal change in the currently reported risk factors, and concluded with the
message that community acquired CDI may be an increasing source of infection requiring further
study. The results reported by Song et al. provide useful information about the changing trends
of CDI, however bias may have been introduced into this study because diagnosis guidelines of
what is considered to be hospital versus community acquired changed within the investigated
decade.
A retrospective cross sectional study conducted by Wagner et al. sought to identify antimicrobial
risk factors associated with severity of symptoms among CDI patients. Patients were included if
they received >72 hours of antimicrobial exposure prior to the initial CDI diagnosis and were
categorized into 2 groups; complicated CDI which included patients who had abnormal
abdominal CT or death within 30 days of initial CDI diagnosis, and all other included patients
categorized as uncomplicated CDI patients110. The authors identified that exposure to
fluoroquinolones, and a longer duration of exposure to carbapenems were statistically significant
for patients developing a complicated initial episode of CDI (p-value=0.017; p-value=0.019).
They also identified that patients receiving oral and rectal vancomycin were also at increased risk
of a complicated CDI outcome (p-value=0.018; p-value=0.025)110. These results indicate that
although there is consensus within the healthcare community that antibiotic exposure is a serious
risk for developing CDI, more research is required to elucidate the severity of disease caused by
different antibiotics.
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Predictors of asymptomatic colonization
The epidemiology of asymptomatic carriers in CDI is not fully understood in the current
literature. Research targeting risk factors is largely focused on risk of developing CDI, rather
than risk of becoming colonized. However, colonized, rather than symptomatic, people may be
key to the spread of CDI.
Research geared towards patients with symptomatic CDI is naturally less challenging given that
cases are reported following a CDI diagnosis, compared to research targeting asymptomatic
carriers which requires active surveillance or screening of patients. A study conducted by
Meltzer et al. aimed to identify risk factors associated with becoming an asymptomatic carrier,
prevalence of colonization on admission, and incidence of transitioning from colonized to
symptomatic disease. Rectal swabs were collected from 2,368 patients on admission to a medical
center during a 10-week period112. Of these patients, 3.4% were colonized with C. difficile, with
an incidence of developing symptomatic CDI of 76.7 cases per 10,000 patient days, compared to
4.6 cases per 10,000 patient days among patients not colonized on admission112. Analysis using
multivariate logistic regression identified that increased aged (>85), prior hospitalization, and a
low Norton score (method of assessing patient frailty including mobility, physical/mental
condition, activity, and incontinence) were statistically significant independent predictors of
being asymptomatically colonized112. The authors also identified that patients who were
colonized on admission were also more likely to receive antimicrobial therapy and for a longer
duration compared to non-colonized patients. These data suggest that although being colonized
on admission was relatively low, this group has a significantly higher risk of developing CDI.
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A similar screening study was conducted by Cui et al. at a healthcare facility in Shanghai, China
which screened for CDI and colonization among patients admitted to an intensive care unit
(ICU). Of the 800 patients with collected stool samples, 33 patients (4.12%) were found to have
CDI and 25 patients (3.12%) were asymptomatically colonized109. Examination of medical
records revealed that being an identified carrier had a significant association with prolonged
hospital stay (OR = 1.137), increased number of comorbidities (OR = 36.509), and higher odds
of having received vancomycin treatment (OR = 18.168)109. This study shows that the prevalence
among ICU patients with CDI and those who are carriers is relatively similar, and if we apply
informaton from Meltzer et al, where 3.12% of carriers admitted to the ICU are at an increased
risk of transitioning to symptomatic disease thereby increasing the overall rate if CDI prevalence.
This study lends support to the importance of implementing screening practices for those at
higher risk. Additionally, this study highlights the importance of interventions targeted towards
the ICU patient population given the comprimised health status associated with an ICU
admission.

Hospital versus community acquired infection
Healthcare acquired CDI (HA-CDI) has historically been the main focus of C. difficile related
transmission research, however within the past decade community acquired CDI (CA-CDI) has
been observed to be increasing in incidence31,32,75,96,113. Kwon et al. conducted a comparative
analysis to determine variation between HA-CDI and CA-CDI by analyzing the medical records
of 593 patients with a positive CDI diagnosis at a hospital in Seoul, South Korea. Patients were
classified as having HA-CDI if symptom expression began >48 hours post hospital admission,
and CD-CDI if symptoms appeared within 48 hours of hospital admission and there was no prior
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hospital admission within 12 weeks prior to CDI diagnosis113. The study found a difference in
multiple risk predictors between CA-CDI and HA-CDI patients. Those classified as HA-CDI
were generally older (60.4 compared to 42.7), had a higher rate of exposure to antibiotics (89.7%
compared to 27.9%) and proton pump inhibitors (49.3% compared to 4.3%) within the preceding
12 weeks prior to diagnosis, and were more likely to have cancer, diabetes or chronic kidney
disease compared to patients with CA-CDI113. This study is consistent with the already
acknowledged risk predictors relating to CDI, but does not provide a clear picture of independent
risk predictors associated with CA-CDI. The knowledge gap persists concerning the existence of
CA-CDI predictors apart from having contact with a healthcare facility, or whether this is the
primary influencing factor for both CA-CDI and HA-CDI.

Diagnosis, testing, & identification
Patients are diagnosed with CDI following both clinical manifestation of symptoms and positive
laboratory tests1,24,114). Diarrhea among hospitalized patients is a common complication resulting
from a range of causes other than CDI. Clinical studies indicate that up to 32% of hospitalized
patients develop diarrhea causing significant morbidity and mortality, however <25% of hospital
onset diarrhea (HOD) are caused by CDI115,116. Many hospital policies have implemented a
threshold requiring at least 3 days of continuous diarrhea prior to CDI testing to help reduce the
amount of testing for non-CDI realted illness 24,114,117.
CDI is diagnosed following laboratory detection of C. difficile toxins (usually tcdA and/or tcdB)
from stool samples collected from the patient7,25 (Figure 6). The most used laboratory test
among healthcare facilities is the enzyme immunoassay (EIA) which has a sensitivity of 75-85%
and specificity of 95-100%117,118. EIA is inexpensive, simple to use, and produces results in <3
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hours114,118. Popular EIA that test for C. difficile antigens by testing for glutamate dehydrogenase
have a nearly 100% specificity rate however are unable to distinguish toxigenicity which may
cause misdiagnosis if the diarrhea was caused by something other than CDI1,114,117. Some rapid
EIA tests have been developed such as the C.diff Quik Chek, which includes testing for both
GDH and toxin presence118,119. An additional method for CDI detection is a nucleic acid
amplification test (NAAT) using a polymerase chain reaction (PCR) or isothermal amplification.
NAAT has a sensitivity of 80-100% and specificity of 87-99% for detecting the presence of the
toxin encoding gene, thereby confirming toxigenicity117–119. NAAT is often more time
consuming than other methods such as EIA, and therefore may not be the primary testing method
at some institutions with large case loads.

Treatment and recurrence
Following confirmation of the presence of CDI through symptom manifestation and a positive
CDI toxin detection test, immediate treatment is required to slow symptoms and stop the
infection1,8. Although antibiotic treatment is one of the main risk predictors for developing a
CDI, this is also the recommended treatment upon infection. Historically, both metronidazole
and vancomycin have been used as treatment for mild and severe infection, respectively,
however multiple studies such as a meta-analysis conducted by Nelson et al. in 2017 identified
metronidazole as an inferior treatment for CDI compared to vancomycin8,117,120–122.
An additional medication for the treatment of CDI is the narrow spectrum antibiotic fidaxomicin
which first became available in 2011 and has since been the source of controversy regarding it’s
high cost. Fidaxomicin is a macrocyclic, bactericidal antibiotic which is used to target Grampositive bacteria and has been shown to have a less significant impact on the naturally occurring
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gut microbial flora compared to other antibiotic treatments117,123–125. A study conducted by
Spiceland et al. examined patients prescribed fidaxomicin to determine the efficacy of treatment
in patients with an initial CDI episode and subsequent recurrences. 81 patients from 3 referral
centers were included over a 4 year duration with results obtained through medical record
examination126. Symptom resolution, (defined as ‘response’) following a 10 day fidaxomicin
course, and any recurrent CDI episodes following successful response from initial episode were
examined. Of all patients 90% had a response to the treatment, those without a response had
significantly more prior episodes of CDI (p-value=0.01)126. Only 19% of patients had a recurrent
CDI episode, with those that previously had a history of more episodes more likely to have a
recurrent CDI126. Lastly, patients who had no prior history of CDI had no recurrent episodes
following treatment of fidaxomicin126. This study demonstrate the efficacy of fidaxomicin
particularly in reducing the risk of recurrence.
In 2018 the Infectious Disease Society for America updated treatment guidelines for CDI
moving away from the standard metronidazole and instead recommending oral vancomycin or
fidaxomicin126,127. A systematic review conducted by Momani et al. compared the efficacy
between vancomycin and fidaxomicin to determine superiority in cure rate and recurrence rate.
In total four observational studies were included totalling 2,303 patients127. Fidaxomicin was
associated with a significantly lower CDI recurrence rate with a pooled OR of 0.42 with 95%
confidence intervals (CI) compared with vancomycin. However, there was no indication that
fidaxomicin was superior to vancomycin regarding clinical cure rate with a pooled OR of 1.22
(95% CI)127. Clinical trials to determine the best course of treatment for CDI are still necessary,
however fidaxomicin seems to be the frontrunner in lowering the rate of recurrence.
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An additional variable in treatment consideration apart from cure and recurrence, is the impact of
spore shedding. Environmental contamination is one of the most critical predictors regarding
CDI therefore treatments and intervention must also consider how spore shedding may be
impacted. To address this question, Turner et al. conducted a randomized control trial to explore
whether antibiotic selection impacts infectious shedding by comparing CDI patients treated with
oral vancomycin, fidaxomicin, and metronidazole. The unblinded study conducted a 1:1:1
comparison by assigning a treatment protocol to 33 positive CDI patients in which they were
prescribed 1 of the 3 antibiotics. The primary outcome was a change in environmental
contamination rate and was identified through sequential environmental swabbing on high touch
surfaces in the patient’s room at day 0, day 3, day 7, and continuing every 7 days until discharge.
The secondary outcomes were total burden of contamination, and molecular relatedness of stool
samples compared to the environmental isolates. 31 patients completed the study and 233
environmental isolates were collected. Fidaxomicin and vancomycin were significantly
associated (p=<0.001; p=0.05) with a faster and more immediate reduction in shedding, as well
as overall lower rates of environmental contamination compared to metronidazole. When
examining patient specific changes in environmental isolates during the sequential sampling,
fidaxomicin was found to significantly reduce shedding compared to vancomycin and
metronidazole.
Treatment through use of antibiotics is the primary response to initial CDI and mild cases,
however in the event the infection increases in severity or the patient is experiencing a chronic
severe case, interventions targeting realignment of the gut microbial flora are introduced. A fecal
microbial transplant (FMT) is the most common treatment targeting the gut microbiome with a
consensus that it is the most effective treatment against severe and chronic CDI49,117,121,128. A
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FMT is a procedure in which stool from a healthy donor is implanted into the gastrointestinal
tract of the infected patient. Isolates are administered through an enema or colonoscopy, with
studies finding no distinct difference in the effectiveness of fresh or previously frozen stool128,129.
FMT has also been shown effective when administered nasogastrically however is not the
primary chosen administration route129. FMT works by re-establishing healthy colonization
levels of bacteria by replenishing the natural microbial balance in the microbiome to prevent
further C. difficile proliferation49,128,129. There is currently no consensus on the exact amount,
levels, or which types of bacteria are necessary for the success of an FMT49,50,130. FMT
successfully cures 65-80% of CDI with one treatment compared to 20-25% of a singular course
of treatment with antibiotics129. The mechanisms contributing to success or failure following
FMT remain poorly defined. Park et al. identified a correlation between donor samples which
had higher bacteriophage α-diversity and lower relative abundance compared to donor samples
resulting in a failed FMT130. Additionally, patients with a successful FMT had increased levels of
Clostridia and Bacteroidia and reduced levels of Gammaproteobacteria, compared with
unsuccessful FMT in which the patients had no measurable difference130. Further research into
the mechanisms impacting a successful donation and receipt are needed to better optimize and
streamline the efficacy of this treatment.
Recurrent episodes of CDI occur in the event that the initial CDI episode was never fully cleared,
or that the patient becomes reinfected through continuous contact with a contaminated
environment while maintaining an unbalanced microbiome111,120. CDI recurrence is defined as
more than 1 episode of CDI in which symptoms resolve between the 2 episodes27,111,120,131.
Following the initial infection patients have a 15-25% risk of recurrence depending on the initial
treatment with each subsequent infection elevating the risk of recurrence132. Oftentimes
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healthcare facilities do not test for CDI resolution given that one of the requirements to order a
test is presence of symptoms119,133. Controlling the amount of tests ordered by physicians helps
to reduce overreporting of C. difficile prevalence which can have lasting impacts on the
functionality of a healthcare facility, however it limits our understanding as to whether recurrent
cases are caused by a persistent colonization or reinfection134. Measures to reduce recurrence
include antibiotics, probiotics, FMT, and antibody therapy111,135. Fidaxomiocin has been shown
to be highly effective in reducing the recurrence rate with the same if not higher efficacy than
vancomycin123–126. FMT is also a treatment used to prevent recurrent episodes but is commonly
not selected as an initial treatment and only used in the event of severe infection or chronic
recurrence128–130. Probiotics are mostly used to prevent an initial CDI and are taken as a
prophylaxis treatment prior to antibiotic therapy however some research supports that these may
be beneficial to prevent further CDI episodes119,135–137. Lastly, bezlotoxumab, a monoclonal
antibody established in 2016 has been shown to greatly reduce the risk of patients developing
recurrent episodes125,132,138.
To further understand the potentially regulating effect bezlotoxumab may have on CDI incidence
or reccurance, Zeng et al. used whole genome sequencing to identify if patients treated with
bezlotoxumab following initial CDI infection had a lower risk of reinfection or relapse of prior
CDI. Among 259 recurrent CDI events 19% were from reinfection with a different strain and
76% were relapses of a prior infection132. Patients treated with beloxumab of those who had a
relapsing infection exhibited a significant decrease in the cumulative incidence of reinfection,
compared to patients who had a relapsing infection and were not treated with bezlotoxumab132.
There was no significant difference in the recurrence rate of patients infected with a different
strain among patients who did and did not receive bezlotoxumab132. Given that a large portion of
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recurrent episodes occurred among patients who were never cleared of the primary infection,
coupled with the proven efficacy of bezlotoxumab, these data suggest that the incidence of
reinfection could be drastically reduced with this therapy.

Prevention
An initial response following CDI detection is to prevent further spread by enforcing infection
control measures to reduce environmental contamination. Following identification of CDI,
general infection control measures are elevated to Contact Precautions (CP), a more rigorous
level of infection control than standard precautions, including donning of gowns, gloves, and
face shield, and deep cleaning of the patient room. Units are deep cleaned in the event of an
outbreak on the unit. In the case of asymptomatic carriers, there is no continuous diarrhea to
warrant CDI testing, therefore CP and deep cleaning is not implemented, a possible reason why
carriers may continue to transmit disease. Infection control measures in general are meant to
prevent the further spread of C. difficile in the environment in an effort to halt transmission and
avoid a potential outbreak.
Apart from CP, prevention measures usually target avoidance of an initial CDI event. Currently
the most recommended prevention tactic is establishment of antibiotic stewardship protocols.
Antibiotic stewardship is the practice of regulating unnecessary and/or superfluous prescriptions
of antibiotics when not clinically indicated139,140. The root cause of the majority of antimicrobial
resistant pathogens, including C. difficile, is over-prescription or inappropriate use of antibiotics
which over time causes the pathogen to develop resistance100,141–143. Many studies have shown
that successful implementation of stewardship guidelines significantly reduces the burden of
AMR infections, including CDI. Morgan et al. demonstrated this through examination of
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prescribing trends before and after establishment of a hospital stewardship program and
compared the cumulative incidence of CDI. The study spanned an 8 year period and included all
admitted patients prescribed, or had a physician request to prescribe antibiotic treatment139. The
stewardship program was established in 2016, therefore patients were divided into 2 groups,
those admitted 2011-2016 and those 2016-2019, totaling 21,330 patients. Over the course of the
study 4,021 antibiotic prescriptions were approved and 483 were denied139. The cumulative
incidence of CDI significantly dropped between the 2 study periods from 20 per year to 6 per
year (p-value=0.0005)139. Although additional factors may contribute to the noted decrease in
CDI rate, such as changes to the testing protocol, this quasi-experimental study highlights the
potential success stewardship programs can provide. The study by Morgan et al. lends support to
the growing consensus that amending antimicrobial prescribing practice is critical to prevent
further burden of AMR pathogens.

Current knowledge of CDI spread in hospital and community settings
The vast majority of diagnosed CDIs are nosocomial in nature and occur among hospitalized
patients or those that were previously in contact with a healthcare facility7,25,101. Given that the
significant predictors of aquiring the infection, such as receiving antibiotic treatment, exposure to
a contaminated environment, and an overall weakened state of health, this is unsurprising. C.
difficile is transmitted through the fecal-oral route through direct contact with a person actively
shedding infectious spores, or through indirect transmission caused by coming into contact with
a contaminated environment, such as a hospital room8,23,27,29. C. difficile can also be spread
through inadequate hand hygiene of someone who was in contact with an infectious person or
material, such as a family member or healthcare provider29,144.
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Levels of C. difficile contamination in the clinical environment have been reported to range from
9.7% to 58% of positive tested environmental swabs, depending on location, sampling
methodology, and quality of disinfection23,29,30,144. Hospital rooms in which patients tested
negative for CDI can have the same level of contamination as a patient with active infection30.
This suggests that spores shed from previous patients, spores brought in from the environment,
or spores shed from an asymptomatic patient remain in the rooms despite cleanings between
patients.
A recent study examining environmental contamination was conducted by Wilson et al. to
determine the significance of bioaerosols produced by toilet flushing in hospital rooms with CDI
positive patients. The researchers identified higher concentrations of the bacteria post-flush
compared to pre-flush resulting in significant contamination within the room and air samples145.
Reigadas et al. conducted a similar study to determine the level of hospital contamination
through environmental sampling of rooms with CDI and non-CDI patients. The sampled areas of
the rooms consisted of high touch surfaces such as door and faucet handle, toilet, bed rails, etc.
In total, 246 environmental samples were collected from the rooms of patients with CDI
(‘Cases’), and 230 samples from non-CDI patient rooms (‘Controls’). The researchers found that
a total of 15.34% of environmental samples were positive for toxigenic C. difficile (TCD), with a
significant difference (p-value=<0.05) between samples collected from ‘Case’ rooms (20.72%)
and those collected from ‘Control’ rooms (9.57%)144. The study identified that within the
sampled rooms 21.51% of faucet taps, 18.42% of call bells, 18.29% of bed rails, 7.79% of
doorknobs, and 6.02% of alcohol-based dispensers were contaminated with C. difficile
bacteria144.
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Many cleaning protocols in healthcare settings are increasingly relying on the use of disinfectant
wipes, a generally effective method of sanitation, however given that C. difficile spores are
resistant to alcohol this method of cleaning is ineffective7,8,23,25,81,146. Pre-wetted alcohol-based
wipes are increasingly used in healthcare facilities to clean environmental surfaces and
equipment. To determine if using disinfectant wipes could result in further complications when
used in the room of a C. difficile positive patient, Nkemngong et al. examined the risk of crosscontamination. Pre-wetted alcohol-based wipes with varying levels of sporicidal chemicals were
inoculated with C. difficile spores and wiped across previously sterilized surfaces146. Results
identified that each wipe had some degree of sporicidal effect, however all wipes transferred C.
difficile spores to the previously sanitized surface146. These results indicate that cleaning
protocols meant to support infection control practices may be aiding in indirect transmission and
healthcare facilities should monitor protocols in which pre-wetted wipes are the standard.
An additional source of contamination may stem from asymptomatic carriers. Patients in the
hospital environment have an increased risk of coming into direct contact with a contaminated
environment or infectious individual compared to those not within a healthcare facility. Two
variables are required for developing CDI; the patient has been colonized with bacteria in the
gastrointestinal tract, and there is a disruption in microbial gut flora allowing for bacterial growth
and infection. If a patient is colonized with the bacteria but does not have a disruption to the gut
flora, it is possible for the bacteria to be spread without the clinical manifestation of CDI11,29,97.
These cases are especially difficult to identify and study given that symptomatic expression is a
requirement for receiving a CDI test, therefore critical knowledge relating to this group is
lacking. The majority of studies examining asymptomatic colonization and transmission is done
in the setting of an outbreak when all patients in a unit are sampled. This does not provide
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accurate information on the role of colonization given that during an outbreak the odds of
contamination and transmission will always be significantly higher than during a non-outbreak
period92,94.
Gilboa et al. examined the burden of environmental shedding by asymptomatic carriers by
quantifying the contamination within rooms of cases, carriers, and non-infected patients. In total,
117 rooms were swabbed to detect contamination, 30 rooms from positive CDI case patients, 70
rooms with asymptomatic carriers, and 17 rooms from non-infected patients29. A scale rating of
the level of contamination from high to low was created in order to perform a multivariate
analysis. In total, 41% of the carrier rooms had residual contamination, within which 24% were
considered heavily contaminated, compared to the non-infected patient rooms which had 6%
contamination29. Overall the contamination score was the same for both carriers and positive
cases indicating a similar level of environmental shedding. These data support the hypothesis
that asymptomatic carriers are contributing to CDI transmission when they are not targeted by
infection control measures. Likely, asymptomatic carriers are silently contributing to
transmission events and subsequent outbreaks at rates higher than previously understood. The
endemic nature of HAIs could indicate a possible unaddressed factor hindering the prevention
and continuing the cycle of transmission of these pathogens. To develop clinically effective
evidence-based prevention strategies we must first fully understand the mechanisms of
transmission.
Various studies have recently been published examining asymptomatic carriers during a nonoutbreak setting through use of a screening protocol, however these studies lack temporality by
only screening for a short duration thereby not providing a comprehensive picture93,103,109,112. An
additional knowledge gap pertaining to understanding asymptomatic colonization is the lack of
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analysis on the genomic level. Few studies have examined colonization using genomic
sequencing techniques and the ones that have lacked temporality11. Further studies are needed to
understand molecular relatedness to deepen our understanding of the mechanisms of carriage and
transmission.
Research to study the mechanisms of transmission and contamination causing CDI is
predominantly focused on the healthcare environment. Recently however there has been a
reported increase in the incidence of community acquired CDI therefore research efforts must
expand to include this often overlooked source of transmission. Gupta et al. conducted a
population based study to determine the main sources of CDI during 20009 to 2011 and
identified that 41% of hospital onset CDI was community acquired96. A decade after this study
was published we continue to see a rise in the prevalence of community acquired CDI and
although rare, are beginning to see cases from patients with no history of contact with a
healthcare facility, who have not travelled, and have not been in contact with an infected
individual.75,147 The majority of community acquired cases are from patients who have had some
level of contact with the healthcare environment, such as an outpatient facility, and oftentimes
have comorbidities, such as crohn’s disease and ulcerative colitis75,96.
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Figure 2 Causal loop diagram
Causal loop diagram exploring the relationship of balancing and reinforcing associations
of hypothesized exposure variables and C. difficile infections in the hospital environment.
Arrow color signifies the positive or negative associated variable relative to the arrow
direction. The only negative arrow reducing the prevalence of CDI is associated with the
contact precaution variable. This indicates that all other variables have a positive
association and reinforcing relationship on the prevalence of CDI in the hospital.
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Figure 3 Diagnostic testing methods
Laboratory diagnosis of C.difficle relies on identifying C. difficile associated toxins and/or a
specific enzyme. Tests such as an enzyme immunoassy (ELISA) work by identifying the
presence of the C. difficile associated enzyme glutamate dehydrogenase (GDH). This enzyme is
present in all patients who are infected with C.difficle, however presence of this enzyme alone
may not be enough to diagnosis C.difficle as being the cause for a diarrheal illness. Toxin A and
toxin B are present when the bacteria are actively producing the toxins which result in
symptomatic disease. The C diff Quik Chek test identifies both GDH and toxin presence and is
used in many clinical laboratories. The PCR test also detects for the toxin genes through nucleic
acid amplification tests (NAAT).
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Section 3: Genomic analysis of C. difficile evolution and spread
Whole genome sequencing methods
Whole genome sequencing (WGS) is the process of determining the makeup of the entire DNA
genome of an organism148,149. WGS has revolutionized the way we study and understand the
spectrum of the living world and has been implemented in a range of sectors such as
environmental organisms, food, animals, and pathogens150. Since the 1990s genomic analysis of
pathogens has allowed better understanding of genetic relatedness and evolution of disease
(Figure 7).

First generation sequencing
Genomic technology continues to advance each year providing more in-depth coverage and
accuracy. Genomic sequencing first began using the Sanger method, named after Fred Sanger
who developed the method in the 1970s148,150. The Sanger method, also known as the chaintermination of dideoxy method, uses fluorescently-marked dideoxynucleotides (ddNTPs) to
replicate chains of DNA resulting in multiple short strands of DNA148,150. The chains are created
by terminating the replication based on recognition of the complementary base. Using gel
electrophoresis, the bases are identified and ordered based on size and color associated with each
base to create the read-out of the DNA chains148,150. This method is referred to as First
Generation Sequencing (FGS) and is utilized for low-throughput, short-read, and targeted
sequencing148,150. The Sanger method can only sequence a singular DNA fragment at a time,
resulting in higher costs and longer wait times compared to other sequencing methods that would
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later be developed148,150,151. This sequencing method is highly accurate but is costly and time
consuming.

Second generation sequencing
Second Generation Sequencing (SGS), also known as Next Generation Sequencing was
introduced in 2005 and solved many issues of FGS, such as cost, time, and data production. NGS
automates DNA cleavage and amplification, and produces millions of short-reads in parallel in a
much shorter turnaround time compared to FGS with results detected directly through a
computer system cutting out the need for gel electrophoresis148,150,151. In order for NGS to read
long stretches of DNA, the genome has to be fragmented and amplified in random clones of 75
to 400 base pairs, which is why SGS is known as short-read sequencing, which are then
assembled in a contiguous sequence using bioinformatic tools149,150. The ability for SGS to only
produce short-read sequencing can introduce preferential amplification for repetitive DNA
fragments and make it difficult to identify changes within the genome which is a major limitation
when examining structural variation149,151. Additionally, SGS does not produce adequate overlap
sequences between fragments which limits reconstruction of complete genomes given that reads
do not span repetitive regions such as mobile elements or prophages149,151. This results in less
accuracy when studying the entirety of the genome149,151.

Third generation sequencing & assembly
Third generation sequencing (TGS) differs from SGS by immobilizing the sequencing machinery
rather than the DNA molecule (as is the case with SGS), and tracks the sequencing of individual
DNA molecules which produces longer sequences of 5 to 30 kilobase pairs per read152,153. Long
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read sequencing (LRS) methods sequence a single molecule at a time thereby eliminating the
preferential amplification of repeat framgements seen in SGS and produce longer overlap
sequences resulting in better, more thorough assemblies151,154. LRS is performed using nanopore
technology, released by Oxford Nanopore in 2014, or single-molecule real-time sequencing
(SMRT) technologies, released by Pacific Biosciences (PacBio) in 2011151.
TGS technologies are faster and more cost effective than FGS and many SGS methods, however
they usually have an error rate of upwords of 15%152,155,152,156. Given that the errors are randomly
distributed, the error rate can be reduced by generating multiple passes of circular consensus
sequencing reads, a coverage of 15 passes can yield >99% accuracy152,156. PacBio sequencing
technology is especially useful for de novo assembly in which there is no reference genome by
which to order the DNA fragments156. With this technology the sequence reads are assembled as
contigs, a series of clusters of overlapping DNA sequences which when grouped together
recontrust the sequence of a region of a chromosome150,152,156. The coverage quality is dependent
on the amount, size, and continuity of the contigs, higher coverage reads indicate there are less
gaps within the data and generates a more complete genome150,152,156. Additionally, PacBio has
the advantage of circular sequencing which results in higher quality singular molecule
sequences152.

Short read versus long read sequencing
Illumina is a widely adopted NGS short read sequencing (SRS) technology which uses
sequencing by synthesis technology for short DNA fragments157. The sequencing process occurs
inside a glass flow cell lined with oligonucleotides (short nucleotide sequences) which hold the
DNA strands in place while a reversible dye-terminator identifies single bases to build the DNA
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strands150,151,154,158,159. Advantages of using SRS include highly accurate results with high
throughput, and efficiency for building phylogenies158–160. SRS technologies such as Illumina are
often used to sequence large quantities of data such as large-scale studies of disease in the
hospital setting. SRS is adequate and effective for fast and inexpensive sequencing in the case of
a large sample load in which there is a well defined reference genome159.
LRS can sequence an average of over 10kb in a single read compared to the average of SRS
which has the read capacity of 150-300bp per read154,155,161. This distinction allows LRS to cover
the same gene in fewer reads, thereby resulting in less alignment and mapping errors161.
Additionally LRS can provide increased accuracy for genes with long tandem repeats and
extreme GC-rich regions154,160,161. The primary distinction between LRS and SRS is the
difference in read length capacity154,160,161. LRS is overall the superior method for assembly
given the advantages in mapping certainty, detection of structural variants, and improved de
novo assembly154,160,161.

Comparative genome analysis and outbreak detection
Long-read WGS allows for analysis of entire genomes which can reveal variation in lineage and
genes which may correlate with pathogenicity or antibiotic resistant phylogenies154,160,161.
Genomic sequencing technologies have become an invaluable tool in precision medicine and
have advanced the accuracy and effectiveness of outbreak management. Historically, clinical
microbiology laboratories performed a range of testing methods to characterize bacterial strains
including serotyping, susceptibility testing, and mass spectrometry, which are valuable tests to
deliver accurate phenotypic information162. These testing procedures lack the granularity that can
be provided by WGS to identify the relatedness between 2 genomes to definitively identify a
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transmission or outbreak12,70,162. Identifying the strain type is useful information, however in the
presence of a common strain such as the C. difficile NAP1 strain, multiple patients may be
infected with the same strain but a deeper resolution is required to determine the level of genetic
relatedness.
Bacterial genomes from the same organism share a common set of genes known as the core
genome154,163. Differences between genomes of the same organism can occur for reasons such as
homologous recombination and point mutations12,164,165. Recombination occurs when bacterial
genomes exchange genetic material, and point mutations include single nucleotide insertion or
deletion events and single nucleotide polymorphisms (SNPs)59,166,167.

Variance between

genomes of the same organism is referred to as the accessory genome which can also be caused
by large scale insertions or deletions, rearrangements, and extrachromosomal elements such as
phages, plasmids, and mobile genetic elements154,168,169. The makeup of the constant core
genome and all observed variance of accessory genomes is referred to as the pangenome170,171.
A popular method of using WGS to identify transmissions and outbreaks is by comparing the
SNP distance between highly related genomes168 (Figure 8). Following sequencing, assembly
and alignment are completed through use of publicly available or custom pipelines. The core
genome of an isolate thought to be involved in the outbreak becomes the reference genome of
which the rest of the genomes are aligned with35,164,172. The number of SNP differences within
the core genome can then be quantified to determine the genetic relatedness between genomes168.
There is currently no formally recognized number of SNP distances to be considered genetically
related, however many studies average 2-7 SNPs to define transmission, with some studies
considering as many as 17 SNPs as transmissions157,168,173–175. Transmissions defined using SNP
distance vary across organisms given that genomic variance can occur for a variety of reasons
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and at different rates depending on the organism10,12,160. Combining transmission data with
spatiotemporal data to identify the root of the transmission, such as a shared hospital unit, is a
significant advantage in outbreak management and further the development of evidence-based
infection control strategies.
Strain detection and genomic analysis of toxigenic C. difficile bacteria is important in
understanding the epidemiology and evolution of C. difficile strains which may indicate
important public health implications such as treatment efficacy, transmission dynamics,
virulence, and pathogenicity157,168,173–175. LRS is a vital tool to identify outbreaks which may
otherwise remain undetected. It is imperative for clinical practice guidelines to incorporate
sequencing technologies to further understand outbreaks and break the chain of transmission.
Current infection control and detection protocols involving investigation of cross contamination
events leading to a reactive response such as unit decontamination. Although this response may
limit exposure in the short-term, it is an acute fix for a larger issue to identify the route of
transmission and where the bacteria came from in the first place. Implementing WGS will allow
clinicians to delve deeper into the chain of transmission and uncover the trajectory of how the
infection moved between individuals to identify the origins and order of infection to better
understand when and where the transmission occurred and avoid future outbreaks.
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Figure 4 Sequencing techniques
Sequencing technology has been advancing since the 1990s with the introduction of Sanger Sequencing
technology. Newer technologies have introduced the method of long read sequencing, such as PacBio and
Oxford Nanopore, which is effective when reading the entire genome. Both short and long read
sequencing technologies are used in research and have varying benefits depending on the goals of
analysis.
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Figure 8 Outbreak analysis using genomic sequencing
Genomic sequencing is an effective tool used to track outbreaks and identify the level of clonal
relatedness among isolates. This figure illustrates a common visualization method to depict the size of a
transmission cluster and the nucleotide distance of patients within the clusters. In this instance a threshold
of being included in a cluster was <4SNV. Patients are listed on the top and side with the same isolate
being matched in the middle. The more muted the colored box, the further isolates are apart in SNV
distance.
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Chapter 3: Methodology
Ethics approval and consent to participate
The study protocols were reviewed and approved by the Institutional Review Board (IRB) within
the healthcare system this study was conducted within, and the CUNY School of Public Health
(SPH) IRB. The IRB approved the collection and bacterial genome sequencing of discarded
CDI-positive stool samples by the Pathogen Surveillance Program (protocol HS# 13-00981) and
prospective collection of discarded stool samples from ICU patients (protocol HS# 15-00371), as
defined by DHHS regulations. A waiver of authorization for use and disclosure of protected
health information (PHI) and a waiver of informed consent was approved based on the criteria
that the use or disclosure of PHI involved no more than minimal risk to the privacy of
individuals, and because the research could not practically be conducted without the waiver and
without access to and use of the PHI. The CUNY IRB deemed the data analyzed in this
dissertation as exempt based on the minimal risk towards participants, de-identified PHI, and a
data transfer agreement approved by both healthcare system and CUNY SPH IRBs. The research
conformed to the principles of the Helsinki Declaration.
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Section 1: Specimen selection, collection, and storage
The data analyzed in this study was collected through prospective sampling of discarded stool
specimens from ICU patients performed between September 2015 to September 2019 (Figure
9). Additionally, discarded stool specimens were collected from the Clinical Microbiology
Laboratory (CML) from patients with a history of ICU admission who tested positive for a CDI
as part of standard of care. Specimens collected from patients during admission to an adult ICU
were used to determine asymptomatic carrier prevalence through a screening protocol developed
for use in this study.

Specimen collection sources
The healthcare system examined in this study is a 1141-bed tertiary and quaternary care facility
with 8 ICUs totalling a 104-bed critical care capacity. The ICU patient population was the
selected participant focus for this study due to the increased risk of these patients developing a
CDI as previously reported11,16. The ICUs support a multitude of medical needs and include the
Cardiac Intensive Care Unit (CICU), Cardiothoracic Surgical Intensive Care Unit (CSICU),
Cardiovascular Intensive Care Unit (CVICU), Cardiac Surgery Intensive Care Unit (ACT6),
Medical Intensive Care Unit (MICU), Neurosurgical Intensive Care Unit (NSICU), Surgical
Intensive Care Unit (SICU), and Transplant Intensive Care Unit (TICU).
Clinical Microbiology Laboratory collection protocol
Stool specimens were collected from ICU patients through 2 independent sources. The first
collection source was samples collected from the CML. Through partnership with the CML, a
daily report was generated which included information on any positive CDI test result from a
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patient who was admitted to, or had a previous admission to an ICU within the study window.
After the CML was finished processing the specimen under the guidelines of standard of care,
the would-be discarded specimen was collected for future analysis. Specimens were stored in a 80°C freezer located at our onsite laboratory. Each specimen was re-tested to validate the
presence of C. difficile in order to conclusively define these patients as cases in the study.

Intensive Care Unit sample collection protocol
The second collection source was prospective surveillance samples collected from patients for
the duration of an ICU admission regardless of CDI history. Through partnership with the ICU
nursing staff, I implemented a protocol for daily collections of discarded material for every
patient admitted to one of the 7 ICUs for the 4 year study duration. Each ICU was provided with
a mobile cart containing pre-labeled 5ml collection containers, individually packaged sterile
collection spoons, and resealable plastic bags to store the collection container after the specimen
was collected. A standard protocol in the hospital is to print patient identification labels for each
unit admission, these labels were adhered to the specimen collection bags by nurses after the
sample was collected in order to identify which patient and ICU the specimen was collected
from. Finally, the nurse deposited the labeled bag containing the specimen in a -20°C freezer
which was provided for each unit. The freezers were located in the soiled utility room of each
ICU under the guidance of infection control protocols for the management of biological waste
material. The specimens were picked-up daily from each ICU and transported to our onsite
laboratory.
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Specimen storage
After the specimens arrived at the laboratory from either an ICU or the CML, the number on the
pre-labeled collection container and the patient medical record number (MRN) listed on the
patient label adhered to the specimen bag were entered into a database to connect the specimen
with the patient. The database then generated a de-identified ID in which to anonymously catalog
the specimen. I then stored the speimens in the private laboratory freezers at -80°C.
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Figure 5 Timeline of case patients
Timeline indicating the patients with positive CDI test results and were admitted to an ICU between
September 2015 to September 2019. Time is represented on the X-axis with each row representing
a unique patient. Recurrent cases are included on the same row for the patient. Red circles
represent the positive samples collected from the CML. Triangles represent the surveillance
samples collected from the ICUs, blue filled triangles indicate the sample was negative for CDI, red
indicates the sample was positive for CDI. This timeline represents all case patients, associated
ICU and hospital admissions, and at which point they were diagnosed with CDI during the 4 year
study window.
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Section 2: Cohort selection, classification, any approach to analysis
Patients were grouped into 3 categories to fully elucidate the differences between those infected,
those who were asymptomatically colonized, and those who were neither infected or colonized.
To analyze asymptomatic colonization, 2 types of patient groups were selected for screening;
matched controls and random controls. Prospective samples that were collected from patients
with no CDI history throughout our study window were either matched to case patients or
randomly selected from the surplus of ICU surveillance specimens to screen for asymptomatic
colonization. In this section I describe why and how these groups were selected.

Selection of case patients and specimens
In order to be classified as a case, the patient must have had a positive CDI diagnostic test result
and ICU admission within the study window (September 2015 to September 2019). The primary
case specimens examined in this study were collected from the CML, however given that
samples were collected from all admitted ICU patients, some collected ICU samples belonged to
case patients. There were 6 case patients in which a substituted specimen collected from the ICU
due to a missing CML specimen was used. Occasionally, patients had >1 specimen collected
from either the CML or ICU, resulting in a total of 425 C. difficile positive isolates for which the
genome was sequenced from 325 case patients. For the remaining case patients without a
sequenced C. difficile genome (n=61), samples were either not available (n=25), did not grow C.
difficile cultures (n=29), or failed sequencing (n=7) (Table 1). Specimens collected in the ICUs
also included case patients given that all admitted patients irrespective of CDI status were
sampled. Of the 401 patients with a positive CDI test, there were 818 collected specimens from
198 case patients in addition to the positive clinical sample. There were 48 of the 818 additional
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samples sequenced from 36 of these patients. Lastly, there were 358 swab samples collected
from 248 of the 401 positive CDI patients, and sequenced 17 samples from 17 patients. In the
event that the clinical CDI positive test sample was not available to us, failed the sequencing or
assembly, or did not grow, one of the additional collected stool or swab specimens were
substituted if they were collected within 2 weeks of the positive CDI test. 10 stool samples and 4
swab samples were used in the analysis as substitutions for the positive CDI test sample.

Section of matched control patients and specimens
To examine carriers and non-infected patients to cases, I chose to split the patients which would
be screened for colonization into 2 groups. The intent was to increase the generalizability of the
findings by having 1 group with similar patient characteristics to cases, and 1 group representing
the average ICU patient. This enabled us to evaluate asymptomatic carriage among patients with
similar clinical characteristics to cases, as well as the carriage rate among the ICU population to
determine if patient characteristics associated with being a case had any association with being a
carrier. Among the ICU patients that were not diagnosed with CDI during the study period and
had collected specimens for, a subset of patients were matched to cases based on age, sex, and
admission to the same ICU within 3 months from the case patient. A 2:1 matching scheme was
used by matching 2 non-case patients to cases. This group became our matched control group.

Selection of random control patients and specimens
The final group for selection was random control patients which were meant to represent the
general ICU population. Additionally, given that an aim of this study was to determine if carriers
contribute to CDI transmission by introducing spores into the ICU, only specimens that were
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collected within the first 4 days of the patient’s ICU admission were selected. This window was
chosen based on clinical infection control definitions of determining pre-infection versus withinunit transmission. The random control patients were selected from the surplus of ICU specimens
collected which had not been identified as a case or selected as a matched control. To select this
group I performed a simple power calculation in SAS software based on the number of possible
specimens avalible for selection (n=1,231), to determine sample size, oversampling by 10% to
account for potential laboratory error or unavailable samples, and determined that 190 patients
per unit (1 specimen per patient) were needed to accurately determine the overall carrier rate
among ICU patients sampled in the 4 selected ICUs. The final 190 patients from each ICU were
selected using random sampling selection with ICU stratification with R software 176. 690 unique
patient samples from the random control group were included in the cohort analysis.

Analysis description and approach
A primary goal of this study was to explore differences between ICU patients who tested positive
for CDI, were identified as being asymptomatically colonized, or were neither colonized or
infected on the demographic, clinical, and genomic level. To begin this analysis, I separated the
group of patients who were eligible to be tested for colonization status (those who did not have a
positive CDI test) into two categories, thereby creating matched and random control groups as
described above. During the course of this initial selection phase I identified a disparity across
the number of specimens collected in each ICU and determined that the source of the uneven
collection was due to variation in unit participation and nursing workload. To ensure each patient
had an equal chance of being selected for screening, I restricted the analysis to the 4 ICUs with
the highest number of unique patients sampled across the groups, these were MICU, SICU,
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NSICU, CCU. The disproportion of specimens collected will likely not introduce bias given that
patients who did not have specimens collected was not related to C. difficile, and was random
error rather than systematic. This restriction was applied to cases, matched controls, and random
controls to increase comparability for the clinical and descriptive analysis, however positive case
samples from all ICUs were included in the genomic and transmission analysis.
The final analysis consisted of patients separated into three groups; cases, matched controls, and
random controls, for which I performed two independent analyses. I first examined the groups
through a cohort analysis which only include the 4 ICUs with the most amount of samples
collected (described above) for the cases, matched controls, and random controls. I implemented
this restriction due to the imbalanced number of samples collected across the ICUs. After
identifying the asymptomatic carriers through screening the matched and random control groups,
I examined the differences between carriers, cases, and non-infected patients to identify
significance and possible predictors. Within this analysis I explored the epidemiological,
demographic and clinical characteristics between the groups (cases, matched control carriers,
matched control non-carries/non-infected, random control carriers, and random control noncarriers/non-infected). There were 48 case patients that were excluded if there was no ICU
admission within 1 of the 4 selected ICUs, or if the CDI positive test date was >3 months from
an ICU admission. I included 353 case patients in the cohort analysis restricted to the 4 ICUs,
and 495 matched control patients with unique samples in the cohort analysis. For the random
control group 111 samples were excluded from the cohort analysis that were collected >4 days
from the start of the ICU admission, and 42 samples were missing and excluded from both the
cohort and transmission analysis, equalling a final total of 690 random control patients.
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Following completion of the cohort analysis, I explored the transmission dynamics among
carriers and cases by performing LRS PacBio sequencing to investigate significance on the
genetic level. To accomplish this, the non-carriers/non-infected matched and non-carries/noninfected random control patients were removed given the analysis was based on sequencing
results of the C. difficile genome, and removed the ICU restriction to include all case patients
from the remaining ICUs. Using the results from genomic sequencing I compared strain type,
outbreak clusters, reinfection, and exposure similarities. I performed qPCR to screen 1087
specimens from the 495 matched controls patients, and 690 random control specimens for C.
difficile colonization. 146 specimens from 127 matched control patients amplified, and 102
specimens from unique random control samples amplified. I performed the rapid Quik Chek
immunoassay on the amplified samples and detected toxin and antigen presence in 40 matched
control patients and 57 random control patients. I cultured the samples on C. difficile selective
agar plates and transferred to sheep's blood agar plates after 48 hours of growth. I selected one
colony per sample from the blood agar plates and performed molecular biotyping.

58

Table 1 Collected samples
Cases
ICU

Patients

ICU 1

2,321

(2397)

ICU 2

2,696

(2639)

ICU 3

1,532

(1258)

ICU 4

2,128

(842)

ICU 5

1,334

(523)

ICU 6

208

(359)

ICU 7

387

(541)

ICU 8

20

(205)

Total

Seq

Matched controls

Random controls

Tot

Seq

Tot

Seq

Not Seq

ICU

54

(63)

48

(45)

(18)

Neg

171

0

Neg

172

0

(17)

Carr

18

18

Carr

8

8

(5)
(6)
(5)
(3)

Neg
Carr
Neg
Carr

60
7
70
3

0
7
0
3

Neg
Carr
Neg
Carr

156
21
165
11

0
14
0
11

(16)

Neg

154

0

Neg

140

0

(24)

Carr

12

12

Carr

17

14

(4)

6
1
5
4
7
4
2
1
3
1
5
0

Other

59

(78)

44

(61)

ICU
Other
ICU
Other

24
27
14
27

(24)
(37)
(16)
(34)

20
20
10
25

(19)
(30)
(11)
(31)

ICU

67

(70)

54

(54)

Other

81

(107)

66

(83)

ICU

4

(4)

4

Other
ICU
Other
ICU
Other
ICU

13
2
1
14
10
3

(13)
(3)
(1)
(16)
(12)
(3)

10
2
1
11
8
2

(10)
(3)
(1)
(11)
(11)
(2)

3
0
0
3
2
1

(3)
(0)
(0)
(5)
(1)
(1)

Other

1

(1)

0

(0)

1

(1)

(0)

Table displaying the number of samples collected, number of patients the samples were collected from,
and location of the collections for each group.
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Section 3: Specimen screening to detect C. difficile colonization
In order to ensure accurate classification of asymptomatic carriers, I first performed laboratory
testing on specimens with a known concentration of C. difficile to identify a baseline threshold
for positivity, followed by a 4-step testing protocol. The protocol consisted of DNA extraction,
real-time quantitative PCR (qPCR) testing, microbial culturing, and molecular biotyping. A
detailed description of the process to identify carriers is described in this section.
Primary screening to detect C. difficile colonization
Stool samples were collected daily in 5mL tubes by nursing staff in the adult ICUs and
immediately stored at -80°C until use for extraction. To ensure the accuracy of results I first
performed a preliminary screen of 1,638 previously extracted DNA samples using real-time
qPCR from cases and matched control patients to determine a valid amplification cycle threshold
to identify carriers during the screening process.
The first step in the 4-stage testing process was to perform DNA extraction for use in qPCR
testing of the selected stool specimens. This was completed by collecting ~4mm of material
directly from the stool specimen and extracting the DNA using 200ul of elution solution from the
MagMAX Microbiome Ultra Nucleic Acid Isolation Kit (Applied Biosystems), on the
KingFisher Flex benchtop automated extraction instrument (Thermo Fisher Scientific). The
process of DNA extraction was necessary for the first step of the testing protocol to determine
through qPCR if C. difficile associated toxins were present in the extracted DNA. The isolates
were prepared for qPCR by adding 5uL at 2X of TaqMan Fast Advanced Master Mix (Applied
Biosystems), 0.5uL of custom mixed primer and probe at 20X, 3.5uL of nuclease free water, and
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1ul of DNA for a final reaction volume of 10uL. Triplicates were created for each sample and
loaded onto a MicroAmp Optical 384-Well Reaction Plate. Primers and probes for detection of
the tcdB gene related to C. difficile were selected from conserved regions of previously
sequenced genomes which I identified using Qiagen CLC Main Workbench (FP5’GCCAAAGTTGTTGAATTAGT;

Probe-5’CTCTTTGATTGCTGCACCT;

RP-

5’CTTAGCTTCTATTTCTTGTCTT). qPCR amplification was performed on ViiA 7 Real-Time
PCR System, beginning at 50°C for 2 minutes and at 95°C for 2 minutes, followed by 40 cycles
of 95°C for 1 second and 60°C for 20 seconds, ending with a hold at 4°C.
For each isolate, we averaged the cycle threshold (Ct) value of the triplicates identified in the
qPCR to determine if the isolate should move forward with the next step of testing. This
determination was made based on the earlier sensitivity testing using known positive and
negative C. difficile samples, and nuclease-free water samples to determine a valid Ct threshold.
I concluded that an amplification of more than 50 cycles was sufficient to establish there was no
presence of C. difficile in the sample. Next, isolates that were below an average of 50
amplification cycles in the qPCR screen were tested for the presence of glutamate dehydrogenase
antigen, tcdA, and tcdB using the Quik Chek Complete Enzyme Immunoassay Rapid Test Kit
(TECHLAB). The isolates in which C. difficile antigen and/or toxin was detected were selected
for culturing using the original stool specimen for the final validation steps.
Validity testing for C. difficile colonization using microbial culturing and biotyping methods
The final steps to ensure the validity of specimens identified as colonized with C. difficile
involved further testing of the original collected material. Stool specimens underwent culture for
C. difficile using ethanol shock culture method, adapted from Griffiths et al.54 Briefly,
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approximately 80mg of solid stool (50 µl liquid stool specimens) was added to 0.5 ml of 70%
ethanol wash and the sample was vortex mixed and incubated at room temperature for 20
minutes. A loopful was then cultured onto C. difficile selective agar (CDSA, Becton Dickinson,
Franklin Lakes, NJ) and the plates were incubated anaerobically at 37°C for up to 72 hours. A
single colony was selected from the C. difficile selective agar plate and subcultured onto a
Trypticase™ soy agar with 5% defibrinated sheep blood plate (TSA II™, Becton Dickinson,
Franklin Lakes, NJ) and incubated for 48 hours. Lastly, colonies presenting the characteristic C.
difficile odor, appearance, and fluorescence under UV illumination were confirmed via MALDIToF mass spectrometry on a Bruker biotyper, a well defined method implemented for
microorganism identification and quality control. For long-term storage, individual colonies were
then emulsified in tryptic soy broth containing 15% glycerol and stored at −80°C.
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Section 4: Genomic sequencing and transmission identification
Preparing DNA isolation for sequencing
Following confirmation of the presence of C. difficile toxin the next step was to prepare the DNA
for genomic sequencing. Specimens were cultured on CDSA plates and incubated anaerobically
for 72 hours. Colonies were then resuspended in bacterial lysis buffer (2 mM EDTA; 20 mM
Tris-HCl pH 8.0) with RNase cocktail (1.5U RNase A and 60 U RNase T1; Ambion, Foster City,
CA, USA), 3.5 mg/ml lysozyme (Sigma-Aldrich, St. Louis, MO, USA) and 200 U mutanolysin
(Sigma-Aldrich, St. Louis, MO, USA). The bacterial suspension was then vortexed and the DNA
extracted using the DNeasy Blood and Tissue Kit (Qiagen, Hilden, Germany) using
manufacturer instructions for the extraction of gram positive bacteria. DNA concentration was
measured using a Qubit® double stranded DNA broad range assay kit and read in a Qubit® 3.0
Fluorometer (Life Technologies Corporation, Eugene, OR, USA). Eluted DNA was stored at 20°C prior to sequencing on the PacBio RSII platform with P6-C4 chemistry.

Genome assembly
LRS data generated through PacBio were assembled using a custom genome assembly and
finishing pipeline.

(https://github.com/powerpak/pathogendb-pipeline). We assembled the

sequencing data by first removing contigs with <10x coverage, and those that were encompassed
within a larger contig168,177. We then circularized the contigs by reorienting the origin of
replication. BLAST+ was used to align the nonredundant nucelotides and identify plasmid
sequences168,177. Variant Call Format (VCF) files generated by pathospot-compare were
converted into profiles using a custom script (https://github.com/mjsull/utilities/blob/
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main/vcf2profile.py). Grapetree (version 1.5) was then used to create a minimum spanning tree
for each cluster. Trees were then concatenated into a single tree by joining each cluster to a root
node with a branch of length 20,000. The process of genome assembly was completed with the
help of laboratory technicians who assisted with creating the original library preparations, and
bioinformaticians who completed the analysis, assembly, and circularization of the genome.

Identification of transmission events
To detect clusters of highly related isolates, open-source PathoSPOT(Pathogen Sequencing
Phylogenomic Outbreak Toolkit) software (https://pathospot.org) was used to identify
transmission events. We defined transmission cases by examining the number of single
nucleotide variants (SNVs) between two genomes which can provide a higher resolution of
genome divergence than MLST or other strain typing methods. To accomplish this, first patients
were compared with multiple sequenced clonal isolates of the same sequence type to examine the
within-host cell divergence caused by the bacterial evolution over time to determine the number
of SNVs that a single clone can develop within a host (Figure 10). The number of SNVs
between serial patient isolates was identified and compared to the this distribution to the SNV
distances between all patient isolates to build a probability distribution of how likely two
genomes are to have originated from a recent clone. This was then used to determine whether
genomes diverge by less than or equal to that number of SNVs to indicate a transmission
occurred. Genomes were clustered based on Mash distance, similar genomes from each cluster
were aligned with ParSNP to construct a phylogeny, and the pairwise distances were obtained
from the tree based on core genome alignments. There is limited genome divergence between
these isolates even after several months, in line with literature that estimates the per-year
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evolutionary rate of C. difficile to be 1.4 mutations172. This observed limited divergence provided
a fixed threshold across all samples, as opposed to a threshold that depends on the time between
the isolates. Based on this analysis it was concluded that if any 2 clonal isolates were ≤4 SNVs
apart they were genetically similar and could be classified as a transmission. This conclusion and
analysis was identified by a previous graduate student and member of the research team who
identified this SNV threshold172.

Analysis techniques
I selected clinical variables relating to CDI risk and outcome established by prior
epidemiological studies, including descriptive statistics to determine trends in demographics,
medications, procedures, diet, prior hospitalization history, length of stay (LOS), and strain type.
I examined patients identified as asymptomatic carriers to determine commonalities both
microbiologically and epidemiologically. Colonized carriers were compared to the total cohort
including those identified with CDI through clinical diagnosis, and patients with no CDI or
colonization to determine significant trends across patient types. Multiple regression analysis
was used to understand the strength of the relationship between the continuous and categorical
exposure variables to inform meaningful conclusions of characteristics associated with each
group outcome (cases, carriers, non-infected). I performed hypothesis testing using the Kruskal
Wallis, and Mann Whitney U/Wilcoxon Rank-Sum nonparametric tests for continuous variables
and χ2 tests for categorical variables.
I chose non-parametric testing for continuous variables relating to clinical admission history, one
way ANOVA test for age and BMI, and chi-square test for categorical variables to conduct a
cross group comparison. Given that the median rather than the mean more accurately represents
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the center of the distribution of the data and the variation in sample size for each group, I did not
assume the data were normally distributed and chose to perform non-parametric statistical
analysis on the continuous variables with the exception of age and BMI. All variables with p ≤
0.05 were considered statistically significant and the odds ratios were calculated. For the
transmission analysis I explored genetically relevant variables between patients including strain
type and nucleotide distance to establish exposure similarities. All analyses and figures were
obtained using R (version 1.3.595)176.
To further explore the significance of transmission clusters we examined unit admission history
to determine the role of prior unit overlap. I first used hypothesis testing to determine a singular
significant unit, followed by the novel Uniform Manifold Approximation and Projection
(UMAP) manifold learning technique for dimension reduction to identify clusters of units. To do
this, units were clustered using 12 sets of parameters (n_neighbors from 2 to 5 and cutoff for
0.01, 0.025, and 0.05). After visualizing these clustering iterations, a parameter of n_neighbors =
3 and cutoff = 0.025 was selected. Due to the small size of the data set, the selection of
n_neighbors was dictated by needing a parameter large enough to generate meaningful clusters,
however not as large to result in all units being grouped within the same cluster. The facet grid
function within the Python Seaborn package was used to visualize the clustering iterations. Each
of the rows in the facet grid corresponds to a different n neighbors value and each of the columns
corresponds to a different cutoff value. The UMAP analysis was completed with the help of a
bioinformatician on the research team, and the results from this analysis were then used in this
thesis.
In order to confirm the parameters did not produce a clustering pattern that varied across each
iteration, the initial clustering pattern generated from the selected parameters was overlaid over
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the clustering from other parameter sets. This was done by carrying over the cluster coloration
from a specific iteration and then applying that to each embedding that corresponded to a cluster.
It was observed that the coloration remained consistent across iterations thereby indicating that
the clustering remained consistent across parameter sets. After finalizing the parameter set, the
names of the specific units included in each cluster were joined with the number of patients
within each unit (including transmission and non-transmission), and the p-values associated with
each cluster. Lastly, I consulted with multiple clinicians to verify that the clustered units were
medically logical, and designated a name for each cluster based on the specialty of the units.
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individuals.

Figure 10 Inter-patient and intra-patient SNV distribution per strain type
Frequency distribution of the number of SVs between any two genomes of the same strain type
(x-axis) among different patients (inter-patient, top) and from serial isolates from the same
patient (intra-patient, bottom). Bars are colored by strain types and black vertical line at the 4
SNVs indicates within-host evolutionary rate clonal cutoff. Figure reproduced from doctoral
work provided by Dr. Elizabeth Webster
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Chapter 4: Results
Section 1: Cohort analysis
Patient and specimen collection
Between September 2015 and September 2019 a high-risk cohort of 10,626 inpatients was
surveilled who were admitted to one of 8 adult ICUs within the 4 year study window and that
had a stool and/or rectal swab specimen collected during their ICU stay or as part of standard
clinical care at any point during their hospitalization (Table 1), (Figure 9). Specimens were
collected from 2 sources, the CML and adult ICUs. Residual stool specimens from the CML
were collected following a positive CDI clinical test result. There were 401 patients who had a
positive clinical test for the presence of toxigenic C. difficile based on PCR and/or enzyme
immunoassay at any point during their hospitalization and that also had contact with an ICU
(Table 2).
Stool and swab specimens were also collected through active surveillance sampling from patients
admitted to an ICU which included non-infected, asymptomatic, and case patients.
Additionally, to understand how common CDI risk factors may impact C. difficile colonization
and transmission I selected two control cohorts from the four most densely sampled ICUs; a
matched control cohort consisting of up to two age, sex, and ICU-matched patients for each CDI
case, and a random control cohort selected among all other sampled ICU patients. There was a
total of 1,586 unique patients selected as a matched control (n=495), random control (n=690), or
case (n=401), and obtained 2,854 stool and 358 swab specimens from the ICUs, and 480 positive
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C. difficile isolates for the cases from the CML. Throughout the course of the study period it was
observed that 9.5% of ICU patients developed symptomatic CDI.
Rate of asymptomatic carriage
In addition to the positive CDI tests collected from the CML which only included case patients,
there were also samples collected from patients who were admitted to an adult ICU. I worked
with the ICU nursing staff and collected a total of 8,382 specimens from a total of 3,133 patients
with no positive CDI test during the study time period. To evaluate the rate of asymptomatic
carriers I screened a group of 690 randomly selected patients, and 495 patients with similar
characteristics to the case patients (described in Methods Section 3.3).
To determine the rate of asymptomatic carriage I screened matched and random controls for
toxigenic C. difficile by PCR for the presence of the tdcB gene. I then tested the original stool
specimens from those identified as positive in the PCR and tested for antigen and toxin presence
using QuikChek. I then validated these results by two-fold culturing and biotyping. Only
specimens which tested positive in all 3 tests were considered as asymptomatic carriers. I
identified the presence of C. difficile in 41 patients from the matched control group, and 57
patients from the random control group (Table 3).
I determined an overall asymptomatic carrier rate of 8.0% in the matched controls, and 8.1%
carrier rate in the random controls. To evaluate whether or not patients entered the ICU already
colonized or became a carrier during the course of their ICU admission, I calculated the carrier
rate among patients with specimens collected within the first 4 days of their ICU admission.
After applying this restriction, I observed no meaningful difference in the carrier rate for either
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group with the matched control group remaining unchanged, and the random control group
increasing by 0.4%.
Demographic and clinical comparison across cases, carriers and non-infected patients
Our first step in comparing the groups was to determine the presence of any significant
differences by clinical or demographic characteristics within the screening groups prior to
conducting an across group comparison. Within the matched controls the only significant
difference I identified was that carriers had 6.5 times the odds of having been prescribed a
mechanically altered diet 14 days prior to when the screened specimen was collected compared
to non-carriers (p-value=0.006). Among the randomly selected controls I observed that carriers
were more likely to be smokers (OR=2.03; p-value=0.001), and less likely to have been
prescribed nitromidozole 14 days prior to specimen collection (OR=0.76; p-value=0.006)
compared to non-carriers. This within-group comparison revealed there was no statistically
significant difference between carriers and non-carriers in both the matched and random controls
based on age, sex, race/ethnicity, BMI, diet and antibiotics. I also examined hospital admission
history and found no difference when comparing length of inpatient hospital stay, length of ICU
stay, number of days admitted to the hospital prior to sample collection, number of overall total
hospital admissions, number of hospital admissions prior to sample collection, and number of
hospital admissions within 1 year prior to sample collection.
I then conducted an across-group comparison of the carriers and non-carriers in the matched
control group and found that the number of total inpatient hospital admissions (carriers: 4.00, [CI
2.00, 9.00]; non-carriers: 10.00 [CI 4.50, 13.00]; p-value=0.011), and the number of inpatient
hospital admissions prior to sample collection (1.00 [CI 0.00, 5.00]; 4.00 [CI 2.50, 8.50]; p-
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value=0.001) were statistically significant. There was no statistical significance observed for
these variables in the random control group.
Next, I aimed to identify demographic and clinical characteristics that may be associated with
being a case, carrier, or not infected. I chose variables previously identified as having been
associated with higher risk for CDI, such as history and length of hospital admission, age,
antibiotics, and diet 7,92,134. I first determined the descriptive statistics of each group such as the
demographic and clinical makeup, after which I performed the Kruskal Wallis non-parametric
test for continuous variables relating to clinical admission history, a one way ANOVA test for
age and BMI, and chi-square test for categorical variables to conduct a cross group comparison
(Table 4). Given that the median rather than the mean more accurately represents the center of
the distribution of the data and the variation in sample size for each group, I did not assume the
data were normally distributed and chose to perform non-parametric statistical analysis on the
continuous variables. The average age for matched control, random control, and case patients
was 62.5, 66.25, and 62.5 respectively. The average BMI observed across the groups ranged
from 26 to 26.5 and female patients accounted for 47.1% of matched controls, 42.5% of random
controls, and 43.4% of cases.
I then combined the carriers and negative patients from the matched and random control groups
to determine significant differences between cases and carriers, and cases and negative patients
(Table 4). When comparing demographic variables of the cases and negative patients I observed
a significant difference in age (p-value=0.013), BMI (p-value=0.007), smoking status (pvalue=0.041), and no significant difference when comparing race/ethnicity, and sex. Case
patients were on avaerge younger in age, had lower BMIs, and were more likley to answer yes
when asked about smoking status. When comparing hospital admission history among the cases
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and negative patients I identified that cases had longer inpatient hospital admissions (pvalue=0.001), longer length of ICU admissions (p-value=0.002), increased number of days in the
hospital prior to sample collection (p-value=<0.001), increased number of overall total hospital
admissions (p-value=0.008), and a higher number of hospital admissions prior to sample
collection (p-value=0.001). I observed that cases and carriers had no significant differences when
comparing age, BMI, smoking status, and type of diet prescribed 14 days prior to sample
collection. I also compared hospital admission and history and did not observe any significant
differences.
I examined antibiotic exposure 14 days prior to CDI onset in cases, and 14 days prior to
specimen collection date in carriers and non-carriers within the matched and random control
groups. The 14 day exposure window was selected based on average time exposed to antibiotics
as a risk factor in developing CDI described in previous research19,178–181. I determined that case
patients had 1.59 (95% CI [(1.13 , 2.23] p-value=0.047) increased odds of having been exposed
to an antibiotic belonging to the fluoroquinolone drug class, 2.19 (95% CI [(1.68, 2.85] pvalue=<0.001) increased odds of having been exposed to an antibiotic belonging to the
glycopeptide drug class, 3.63 (95% CI [(2.8 , 4.69)] p-value= <0.001) increased odds of having
been exposed to an antibiotic belonging to the nitroimidazole drug class, and 0.85 lesser odds of
having been exposed to an antibiotic in the cephalosporin drug class 14 days prior to
the CDI diagnosis date compared to non-case patients. I did not detect significance at the .05
level for exposure to the drug classes carbapenems, penicillin, or tetracycline when comparing
the cases and non-cases. I determined that case patients had 2.96 (95% CI [(1.76 , 4.97] pvalue=0.001) increased odds of having been exposed to an antibiotic belonging to the
nitroimidazole drug class 14 days prior to CDI onset compared to carriers. I did not detect
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significance at the .05 level for exposure to the drug classes fluoroquinolone, carbapenems,
penicillin, tetracycline, or glycopeptide (vancomycin) when comparing the cases and carriers and
the cases and carriers. I performed the same hypothesis testing within the matched and random
control groups, comparing carriers and non-carriers, and found no significant association at the
.05 level between carrier status and antibiotic exposure. These findings support current research
identifying antibiotic exposure as a risk factor for symptomatic infection7,18,19,22,79,178,180,181. The
decreased odds observed among cases with exposure to cephalosporins 14 days prior to the CDI
positive test date compared to carriers is likely attributed to uncontrolled confounders given
previously established research identifying cephalosporin exposure as a risk predictor for CDI.
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Table 2 Case patient specimen collection
Case Patients
CDI positive test samples collected from the CML
Patients
Initial total
401
Specimen not available
25
Did not grow C. difficile
29
Failed sequencing or assembly with no replacement
7
Successfully collected & sequenced
340

Samples
480
25
32
9
414

Table displaying the samples collected from case patients and how many samples were sequenced

Table 3 Rate of asymptomatic carriers of matched and random control patients

Final screened
Asymptomatic carriers

Final screened
Asymptomatic carriers

Matched controls
Patients
495
40
Carrier rate = 8.08
Random controls
Patients
690
57
Carrier rate = 8.12

Samples
1087
41

Samples
690
57

Table displying the patients screened for asymptomatic carrier status and the results of the screen.
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Table 4 Demographic and clinical analysis

Parameter
n
Length of inpatient
hospital stay (median
[IQR])
Length of ICU stay
(median [IQR])
# of days in hospital prior
to sample collection
(median [IQR])
# of total inpatient hospital
admissions (median
[IQR])
# of inpatient hospital
admissions prior to sample
collection (median [IQR])
# of inpatient hospital
admissions within 1 year
prior to sample collection
(median [IQR])
Age (median [IQR])
Sex (%)
Female
Male
BMI (median [IQR])
Smoking status (%)
Never
Not Asked
Passive
Quit
Yes
Race/ethnicity (%)
American Indian or Alaska
Native
Asian
Hispanic or Latino

Cases

Non-carriers

Carriers

353

1088

97

35.59
(44.90)

27.12 (41.28)

5.00 [2.00,
12.00]

4.00 [2.00,
8.00]

8.00 [2.00,
17.00]

5.00 [2.00,
12.00]

6.00 [2.00,
14.00]

4.00 [2.00,
10.00]

3.00 [2.00,
8.00]

3.00 [1.00,
6.00]

2.00 [1.00,
5.00]
62.00
[53.00,
71.50]

2.00 [1.00,
4.00]
65.00 [55.00,
74.00]

28.47
(35.49)
5.00
[3.00,
10.00]
5.00
[2.00,
13.00]
6.00
[2.00,
12.00]
2.00
[1.00,
7.00]

p-value
[cases/
carriers]

0.15
0.001**
0.921
0.002**
0.093

0.008**
0.137
0.001**
0.076

66.00
[53.00,
71.00]

0.279

0.356

0.738

27.00 [23.00,
31.00]

42 (43.3)
55 (56.7)
26.50
[22.00,
31.25]

157 (44.7)
21 ( 6.0)
1 ( 0.3)
140 (39.9)
32 (9.1)

465 (42.8)
126 (11.6)
1 ( 0.1)
396 (36.4)
99 ( 9.1)

48 (49.5)
10 (10.3)
1 (1.0)
25 (25.8)
13 (13.4)

1 (0.3)
11 (3.1)
38 (10.8)

479 (44.0)
609 (56.0)

1 (0.1)
45 (4.1)
152 (14.0)
76

0 (0.0)
4 (4.1)
9 (9.3)

<0.001**
*

0.66

2.00
[1.00,
4.00]

163 (46.1)
190 ( 54.1)
25.00
[22.00,
30.00]

p-value
[cases/no
ncarriers]

0.013*
0.576

0.189
0.064

0.007**
0.041*

0.912

0.5

Native Hawaiian or Other
Pacific Islander
Non-Hispanic Black or
African American
Other or Unknown
White
Antibiotic usage within 14
days of sample (%)
Carbapenems
Cephalosporin
Fluoroquinolones
Nitroimidazole
Penicillin
Tetracyclines
Glycopeptide
(vancomycin)
Diet prescribed within 14
days of sample (%)
Bariatric Step I
Clear liquid
Full liquid
Low microbial
NPO
Bariatric Step II
Consistent carb
Halal
Mechanically altered
Puree
Soft
Dysphagia puree
Heart healthy
Enteral feed
Regular

2 ( 0.6)

2 ( 0.2)

77 ( 21.9)
89 ( 25.4)
133 ( 37.9)

221 (20.3)
271 (24.9)
395 (36.3)

70 ( 21.3)
181 ( 55.0)
59 ( 17.9)

171 (18.6)
602 (65.4)
122 (13.2)

164 ( 49.8)
99 ( 30.1)
8 ( 2.4)

210 (22.8)
306 (33.2)
20 ( 2.2)

258 ( 78.4)

602 (65.4)

1 (0.3)
66 (21.2)
24 (7.7)
2 (0.6)

0 (0.0)
171 (17.4)
31 (3.2)
0 (0.0)

247 (79.2)
0 (0.0)
31 (9.9)
1 (0.3)
6 (1.9)
6 (1.9)
9 (2.9)
16 (5.1)
28 (9.0)
123 (39.4)
79 (25.3)

869 (88.5)
0 (0.0)
89 (9.1)
1 (0.1)
21 (2.1)
35 (3.6)
48 (4.9)
34 (3.5)
52 (5.3)
346 (35.2)
185 (18.8)

0 (0.0)
25 (25.8)
26 (26.8)
33 (34.0)
16 (20.0)
52 (65.0)
9 (11.2)

0.922
0.136
0.203

22 (27.5)

0.001**

32 (40.0)
3 ( 3.8)

0.116
0.788

59 (73.8)

0.455

1 (1.1)
11 (12.5)
3 (3.4)
0 (0.0)

0.918
0.096
0.24
1

77 (87.5)

0.108

2 (2.3)
5 (5.7)
0 (0.0)
6 (6.8)
6 (6.8)
0 (0.0)
5 (5.7)
3 (3.4)
39 (44.3)
21 (23.9)

0.07
0.307
1
0.043
0.043
0.228
1
0.134
0.482
0.889

0.323
0.001**
0.047*
<0.001**
*
0.33
0.955
<0.001**
*
0.545
0.16
0.001**
0.092
<0.001**
*
NaN
0.726
0.977
0.996
0.209
0.179
0.245
0.027*
0.203
0.017*

Comparing the cases and non-carriers from the matched and random control groups to determine
significant differences. The analysis is restricted to patients with an admission to one of the 4 ICUs with
the highest rates of sample collections. Kruskal Wallis [nonparametric] test was used for hypothesis
testing for continuous variables, and χ2 test was used for hypothesis testing for categorical variables.
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Section 2: Genomic analysis
Transmission analysis reveals frequent undetected CDI transmissions
To examine the breakdown of strain types and the role of transmissions in the dissemination and
spread of CDI, complete genome analysis of C. difficile isolates obtained from cases and
asymptomatic controls was performed. All specimens collected for patients with ICU contact
during any point in their hospitalization(s) were evaluated to account for the fact that
transmissions and colonization can occur at any point during their stay. There were 425 C.
difficile positive isolates for which the genome was sequenced from 325 case patients.
Occasionally, patients had >1 specimen collected from either the CML or ICU, which yielded a
total of 425 C. difficile positive isolates for which the genome was sequenced the from 325 case
patients. For the remaining case patients without a sequenced C. difficile genome (n=61),
samples were either not available (n=25), did not grow C. difficile (n=29), or failed sequencing
(n=7) (Table 2). Specimens collected in the ICUs also included case patients given that all
admitted patients irrespective of CDI status were sampled. Of the 401 patients with a positive
CDI test, there were 818 specimens collected from 198 case patients in addition to the positive
clinical sample.
There were an additional 48 stool and 17 swab specimens sequenced from case patients that were
collected as part of the ICU active surveillance sampling in the ICUs. Overall, 514 complete
genome sequences were obtained, which included 325 case patients and 89 asymptomatic carrier
patients using PacBio sequencing technology (Pacific Biosciences Technology).
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The genomes were characterized using the pubMLST scheme, which revealed 42 different strain
types (Figure 11A, B). I identified 42 strain types across the 425 CDI positive sequenced
isolates (Figure 11A). There were 4 dominant strain types responsible for the majority (52%)
infections, with MLST 1 (ST1/NAP1/RT0027) contributing 22.5%, MLST 42 contribuing
13.2%, MLST 2 contributing 10.2%, and MLST 8 contributing 6.02%. There were 21 sequenced
samples (6.3%) which did not have an idetified MLST (Figure 11B). The strain diversity
observed is similar to what has been reported in other studies based in the US with NAP1
causing the largest proportion of CDIs, and MLST 42 increasing in incidence across the
country4,47,164,182. The observed rates remained constant throughout the study duration with a
small decrease seen in ST1 (Figure 11B). In the second half of Year 1 of the study the standard
testing procedure was changed from PCR testing to immunoassay which may have contributed to
the relative change in ST1. Pairwise comparison was then used to identify clonally related
isolates that had genomes ≤4 SNV apart, which was defined as a transmission cluster (see
methods for definition of the transmission threshold) (Figure 10). At this threshold, I identified
94 cases and 19 carriers involved in 40 clusters (Figure 11C).
Throughout the course of the study period 21% of the asymptomatic carriers and 29% of cases
with a sequenced genome were part of a transmission cluster, resulting in an overall rate of 27%
of all symptomatic and asymptomatic patients. There were 15 different MLSTs represented
throughout the 40 clusters which exhibited a similar MLST distribution observed among all case
patients (Figure 11D). MLST 1 was the most common strain isolated from the case patients and
accounted for a higher proportion of transmissions compared to all CDI cases. MLST 2 was the
most common strain isolated among the carriers, and was also one of the least common strains
involved in transmission clusters. I observed that the strain distribution remained consistent
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throughout the 4 year study duration. Within the 40 transmission clusters, there were 12 clusters
that included ≥1 asymptomatic carrier. I identified 7 clusters (cluster # 1, 2, 13, 16,19, 36, & 37)
in which a specimen from an asymptomatic carrier was collected after a positive CDI test from a
case patient, 3 clusters in which the colonized specimen was collected before any case CDI test,
and 2 clusters that consisted of only carriers. Patients from 5 of the clusters involving carriers
had admissions to the same unit however none were in the same unit at the same time. The final
transmission cluster involved an asymptomatic carrier that did not share a common unit with
either of the 2 case patients in the cluster.

Asynchronous unit admission is the likely driver of transmission compared to
direct patient overlap
To identify drivers of transmissions I assessed the size, connectivity, time, and shared locations
for each of the clusters. There was substantial variability in the size and extent of each cluster
(Figure 12A), but the overall rate of transmission (25%) was relatively constant for the duration
of the study (Figure 12B). On average, 3 patients were included in each transmission cluster
with a minimum of 2 patients and maximum of 12 patients (Figure 12C). There was an average
number of 113 days between samples within a transmission cluster with a first and third
interquartile value of 38 and 249 days. Across the 40 transmission clusters the minimum number
of days between a CDI positive test/ICU collection date was 2 days, with a maximum number of
1455 days for patients in the same cluster. The largest cluster identified of 12 unique patients had
samples collected from 7 different units with the earliest sample collected in September 2015 and
the latest collected in September 2019 (Cluster # 1, Figure 12A).
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After identifying the transmission clusters, I sought to determine if patients in the same cluster
had overlapping stays in the same unit that could account for the transmission event. I examined
the hospital admission and unit history of patients within the same cluster to identify overlapping
hospital units prior to the positive CDI test result or identified colonization. I extracted the unit
admissions data for each patient prior to the positive test date or date of ICU specimen collection
and performed a comparative analysis to determine unit overlap leading up to infection. To
increase the validity of our analysis I included only the hospital stays in which the infection
directionality was logical, therefore I excluded overlapping unit admission if the overlap
occurred after both patients already tested positive for CDI. First, I observed that 57.5% (n=23)
of transmission clusters did not have patients admitted to the hospital at the same time (Figure
12D), however given that patients can be readmitted to the hospital in close proximity, I
expanded our analysis to days apart rather than restricting by a specific transmission. Therefore,
unit overlap was examined at 5 separate times, if the patients were in the same unit at the same
time (0 days), and if they were in the same unit within 7 days, 14 days, 30 days, and 180 days
(Figure 12E). I observed that the majority (77.5%) of clusters had no patients admitted to the
same unit concurrently (0 days), whereas 75% of clusters had patients admitted to the same unit
within 180 days of each other. These data suggest that direct transmission caused by patient-topatient contact is unlikely given the low rate of patients admitted to the same unit concurrently.
When the overlap definition expands to include patients that were admitted to the same unit
within 180 days of each other, I observed a substantial increase in the rate of total clusters
suggesting that environmental contamination may be a more likely vector for transmission.
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Specific units exhibit increased association with CDI transmissions
I next explored the possibility that some units may be contributing to transmission events at an
increased rate and acting as a reservoir for C. difficile within the hospital. To accomplish this I
investigated all units visited within 6 months, 3 months, and 1 month prior to the CDI diagnosis
or asymptomatic detection. I aggregated the total number of hours each patient spent per unit to
define a continuous exposure variable for the 3 selected time windows prior to CDI. I defined the
outcome as a dichotomous categorical variable based on if the patient was involved in a
transmission cluster or not. I examined this relationship to identify a possible association
between length of stay in a specific unit and involvement in a transmission cluster. I used the
Mann Whitney U/Wilcoxon Rank-Sum Test to compare the medians of hours in units prior to
CDI of cluster and non-cluster patients, including 0 hours if a patient was never admitted to the
unit. There were a total of 99 unique units visited by patients who developed CDI within 6
months, 97 units visited by patients who developed CDI within 3 months, and 87 units visited by
patients who developed CDI within 1 month. I identified 1 unit (‘A1’) that was statistically
significant at the 0.05 level and progressively increased in significance across all 3 time windows
(6 months=0.05; 3 months=0.01; 1 month=0.002).
I first sought to determine if there was a significant relationship of ever being admitted to the
identified significant unit and involvement in a transmission cluster. I found that there were no
increased odds of being involved in a transmission if a patient was ever admitted to the unit
compared to a patient that was never admitted to that unit. I then explored length of time
admitted to the unit as a predictor for being in a transmission cluster. I identified that the odds of
being in a transmission cluster for patients who were admitted to the unit for >1 week were
higher compared to patients who were admitted to the unit for <1 week. Compared to patients
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who were admitted to the unit for <1 week, patients admitted to the unit for >1 week within 6
months prior to testing positive for CDI had 3.15 (CI [0.935, 10.632]) increased odds, >1 week
within 3 months prior to testing positive had 4.05 (CI [1.047, 15.64]) increased odds, and
patients admitted to the unit for >1 week within 1 month prior to testing positive had 7.95 (CI
[1.62, 38.95]) increased odds of being involved in a transmission cluster.
After I confirmed that patients likely become infected in earlier units prior to the unit in which
they test positive, as well as identified that there are units more associated with being in a
transmission cluster, I explored the possibility that there was not just a singular unit, but a
grouping of units resulting in transmission clusters. This was considered in the analysis given
that units are rarely independent. For example, if patients admitted to unit A are frequently
admitted to unit B, units should not be considered independent. This analysis was completed
with the assiatance of 2 bioinformaticians who are members of the research team. We used a
multi-methods approach to group the 99 units visited within 6 months of the CDI among
transmission cluster patients. First, we conducted an unsupervised permutation analysis through
use of the novel manifold learning technique UMAP for dimension reduction to identify units
which patients consistently transferred between (Figure 13A) and grouped them based on
specialty (Figure 13B). The data from the UMAP analysis showed us which units had the
highest density of patients transferring between the same units, which is observed based on the
clusters (Figue 13A). We identified 10 clusters which were grouped into specialties including
Surgical, Cardiac A, Cardiac B, Cardiac Surgery, Radiology, Ambulatory Surgery, Neurology,
Medical/Surgical A, Medical/Surgical B, and Medical Oncology. The units included in the
Radiology cluster are radiological in specialty but did not cluster together in the analysis. This
may be caused by the high frequency of patients repetitively being admitted to a radiology unit,
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however further analysis of this cluster is needed. We next tested the clusters to determine
whether certain unit clusters were more associated with transmissions than others. We observed
that patients admitted to specific units associated with pre- and post- surgical units were
significantly associated with being in a transmission cluster compared to patients who traveled
via other pathways during their hospital admission (Figure 3C). I compared these data to the
overall distribution of CDI diagnoses throughout the hospital and observed that the units
included in the surgical cluster had CDI rates >10% in each year of the study period, however
they were not the units with the overall highest rates (Figure 13D). Upon identifying that the
surgical cluster was a significant pathway, I reexamined the unit admission history within the
transmission clusters. I identified multiple clusters which had at least 1 of the 4 units identified
as part of the surgical pathway cluster, and identified 2 clusters that contained all 4 units with
most patients being exposed to the units prior to CDI (Figure 13E & Figure 13F).

Recurrent CDI is more likely caused by new infection and not an unresolved
persistent infection
I next aimed to identify the rate of recurrent CDI infection, and to determine if patients were
continuously becoming infected or not fully decolonized. Recurrent CDI was defined as isolates
that were collected at least 30 days apart, a threshold commonly used in research examining
recurrent C. difficile111,183–185. Among the 401 patients who had a clinical CDI positive test from
the CML, 39% tested positive for CDI more than once, and 19% tested positive for CDI with
≥30 or more days in between positive tests (Figure 14A). These samples were collected either
from multiple clinical CDI positive tests (n=145), or from surveillance samples collected during
an ICU admission (n=127). There were 76 patients (n=163) that had >1 sample collected over 30
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days apart, of which at least 2 samples were sequenced from 55 patients (n=144), and identified
that 21% (n=12) of patients with samples collected >30 days apart were clonal isolates. The
strain type distribution relating to recurrent CDI was similar to the overall strain distribution with
MLST 1 and MLST 42 accounting for the highest number of cases (Figure 14B). These data
suggest that the majority of patients with recurrent CDI are re-infections, and the remaining
patients were not fully decolonized following treatment from the initial infection.
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Figure 6 Phylogenies of MLST distribution across samples
A) Phylogenetic tree depicting genetic distance of strain types among all sequenced CDI cases;
B) Rate of MLSTs across 4 year study duration; C) Phylogenetic tree depicting genetic distance of
strain types among cases involved in a transmission; D) Proportion of most frequent MLSTs
observed in samples involved in a transmission cluster and samples not involved in a cluster.
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Figure 7 Transmission clusters
A) Timeline depicting 40 transmission clusters across the 4 year study window. Hollow circles
represent asymptomatic carriers identified through surveillance, solid circle represent
symptomatic cases with a positive CDI test result; B) Absolute count of cases and carriers per 6
month window represented on the left axis (bar); percent of patients involved in a transmission
cluster per 6 month window represented on the right axis (line). C) Histogram depicting the
distribution of the number of patients involved in each transmission cluster; D) distance between
hospital stays among patients in the same cluster that did not have an overlapping hospital
admission in which the positive CDI test occurred; E) Percent of the total number of transmission
clusters relative to the number of days patients overlapped in a unit
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Figure 8 Cluster analysis to determine unit pathways of transmission cases
A) UMAP analysis generated through a permutation analysis to identify the presence of clustering
units acting as pathways in which patients admitted to one unit are often admitted to another unit.
Data points represent a 3-dimensional spatial distribution of the units and are clustered based on
density of the amount of patient overlap visiting the same units; B) Description of specialty for each
unit identified as being a part of a pathway cluster; C) Analysis to determine if any of the cluster
pathways were significant for patients involved in CDI transmission cases; D) Plot displaying the
overall CDI rate in the hospital with each unit colored by the cluster they were grouped in; E) Cluster
#2 timeline with units included in the surgical cluster outlined in red and ICUs outlined in black
indicating prior overlap resulting in potential transmission; F) Cluster #4 timeline with units included
in the surgical cluster outlined in red and ICUs outlined in black indicating prior overlap resulting in
potential transmission
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Figure 9 Reccurent CDI cases
A) CDI cases over time for patients with more than one positive CDI test result. Samples are
normalized to day 0 to represent the first sample collected. Connected red dots indicate the
sequenced genome of the sample was clonally related to the prior sequenced sample.
Timeline restricted to patients with recurrent CDI positive test more than 30 days apart from
the previous positive sample; B) Distribution of sequence types among patients with recurrent
CDI and those with no more than 1 reported CDI
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Chapter 5: Discussion & Conclusion
The primary risk factors for CDI include antibiotic exposure, comorbidities, a weakened immune
system, and advanced age, common factors also found in patients requiring ICU
admission1,25,75,186. These patients are not only at higher risk for developing CDI but also at
increased risk of developing more severe outcomes caused by the infection compared to nonICU patients16. I sought to examine differences in patient characteristics among those with
symptomatic CDI, asymptomatic carriers, and non-infected ICU patients to further our
understanding of how disease expression varies across ICU patients. I utilized epidemiological
data and genomic technology to explore transmission and outbreak clusters, environmental
persistence, and colonization dynamics. The cohort analyzed in this study was unique in both the
large size and extensive 4-year period of sample collection which provided the platform for a
rigorous analysis. Applying genomic sequencing technology to explore transmissions and
environmental persistence is a highly accurate approach towards understanding the dynamics of
C. difficile transmission networks. Understanding the dynamic interaction between host,
environment, and pathogen through analysis of a robust clinical cohort can advance public health
development of evidence-based prevention of CDI and may act as future guidance for
understanding and ultimately preventing further burden of HAIs.
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Asymptomatic carriers and environmental persistence
We tracked 401 clinically diagnosed CDIs throughout the hospital and sequenced samples from
C. difficile positive cases. Concurrently, we collected surveillance samples from all patients who
were admitted to an ICU which allowed us to collect samples before, during, and after a patient
was diagnosed with CDI, as well as from control patients without prior history of CDI. These
samples were then either matched to the case patients or randomly selected for screening. After
screening these 2 groups I identified an asymptomatic carrier rate of 8.0% and 8.1%, supporting
previous studies within healthcare institutions in the US identifying a carrier rate of 5-26%.
11,91,92,187,188

.

When I combined the carriers and non-infected patients from the screened groups and compared
them to cases, I observed that factors associated with increased hospital exposure (length of
inpatient hospital stay, length of ICU stay, number of days in hospital prior to sample collection,
total inpatient hospital admissions, number of inpatient hospital admissions prior to sample
collection) were significantly associated with cases compared to non-infected patients. I also
observed a significant association of case patients being exposed to antibiotics compared to noninfected patients. These findings align with previous studies which identify longer hospital stays,
prior hospital admission, and antibiotic exposure as being predictors of CDI16,107,189. When
examining these same variables among the cases compared to carriers we did not observe any
significance. This further supports my conclusion that individual patient factors do not contribute
to asymptomatic status. Based on the similar carrier rate observed among the matched and
randomly selected groups, I concluded there were no significant differences between these
groups. This indicates that clinical and demographic factors specific to the patient do not impact
the chances of becoming asymptomatically colonized compared to not being colonized.
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I identified 40 unique transmission clusters containing clonaly related C. difficile isolates, of
which 12 clusters included an asymptomatic carrier. There appeared to be no significance
regarding when the carrier tested positive within the cluster given that the 12 clusters included
carriers who tested positive before, and after case patients. This indicates that the asymptomatic
carriers may not necessarily be driving CDI transmission, but become colonized during their
hospitalization which may lead to future infection. I identified 2 clusters (cluster # 27 & #31)
which only included carrier patients. In cluster # 31 the patients were identified as colonized with
a genetically identical strain <30 days apart, and in cluster #27 the colonizations were identified
<1 year apart. This may provide evidence that colonized patients may contribute to the spread of
C. difficile in the hospital environment. Environmental contamination may be an even greater
concern among asymptomatic carriers given that only standard infection control protocols would
be in-place since this group lacks the positive CDI test triggering the more robust contact
precautions implemented for case patients. Further study is needed to identify the rate of
transmission and probability of infectious carriers among this group to help shape an effective
strategy to combat environmental contamination when lacking symptomatic evidence.

Environmental persistence as a driver of transmission clusters
Among the 40 observed transmission clusters only 22.5% included patients with overlapping
admission to the same unit, however 77.5% of clusters included patients who were in the same
unit within 180 days of each other (Figure 13E). These data suggest that direct transmission
caused by patient to patient contact is unlikely given the low rate of patients admitted to the same
unit concurrently. When the overlap definition was expanded to include patients that were
admitted to the same unit within 180 days of each other, there was a substantial increase in the
rate of total clusters indicating patients frequented the same units at different times prior to
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infection and that environmental contamination is the most likely source of transmission. The
current standard operating procedure initiates specific unit cleaning protocols following a CDI
diagnosis, however these data suggest this may not be an effective strategy given that the
transmission occurred in an a prior unit.

Reservoir unit pathways increase transmission
Upon observing a significant association with being in a transmission cluster and admission to
unit ‘A1’, I sought to explore the possibility that there was a cluster of units associated with
transmission cases rather than a singular unit. Given that nearly all inpatient hospital stays
include admission to more than 1 unit, I hypothesized that it was not a singular unit associated
with being in a transmission cluster but rather a cluster of units. With the collaboration of of the
research team, we defined unit clusters as multiple units which consistently shared the same
patients which we identified through admission analysis. We confirmed these clusters through an
unsupervised permutation analysis and confirmed the results with clinicians to ensure medical
accuracy. For example, the clusters we identified statistically aligned with the same or highly
similar specialties. For example, the cardiac ICU clustered with the cardiothoracic ICU, and an
orthopaedics unit clustered with a unit specializing in rehabilitation (Figure 13B). We identified
a total of 10 significant unit clusters. We observed a significant association between CDI patients
who were admitted to the surgical unit cluster and a higher likelihood of being in a transmission
cluster compared to CDI patients not in a transmission cluster (Figure 13C).
These findings suggest that the pre- and post- surgical units may have higher levels of
environmental contamination given that clonal isolates were observed in patients who were
admitted to these units months, and in some cases years apart. An additional contributing factor
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may be that the patients admitted to these units undergo procedures which could require longer
hospital stays or antibiotic prescription, both known predictors for CDI8,18,117. Patients admitted
to these units are likely to have more clinical predictors This analysis compared positive CDI
patients to examine unit admission differences in those who were included in transmission
clusters or not, therefore patient comorbidities are likely not a confounder given both groups
were positive for CDI.
Additionally, we compared the overall CDI incidence in the hospital and observed that units
included in the surgical cluster had above-average rates of CDI, however they were not among
the units with the highest CDI rates in any year (Figure 13D). These results support our findings
that these units are specifically associated with transmissions, and not artificially inflated due to
a heightened overall CDI rate. I examined the unit pathway timelines of 2 of the 40 transmission
clusters and observed that patients had overlapping hospital stays in the surgical cluster units
prior to becoming CDI positive (Figure 13E & 13F). An instance such as this may inadvertently
attribute a positive CDI to the unit in which it was detected, rather than the unit in which the
transmission occurred. This can result in misleading outbreak investigations and response such
as cleaning protocols implemented in the incorrect units, and outbreaks left undetected when
deemed unrelated. Using genomic technologies as the primary approach in outbreak
investigations is critical to ensuring under-the-radar outbreaks are detected, and cases of endemic
strains not misclassified as an outbreak. Evidence based pathogen surveillance can assist
infection control to mitigate a waste in resources and work towards total reduction of HAIs.
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CDI recurrence is more likely caused by a new infection rather than unresolved
previous infection
I identified that 85.5% of patients with recurrent positive CDI tests >30 days apart were infected
with non-clonally related C. difficile. These data suggest that susceptible patients, such as those
with a history of an ICU admission, are continuously encountering C. difficile and becoming
reinfected with a new strain rather than exhibiting relapses of an unresolved initial infection. It is
not clear whether the reinfections are community or hospital acquired, however given that ICU
patients have significantly longer hospitalizations which elevate the opportunity for exposure, it
is more likely that the reinfections are hospital acquired11,16,76,109. Additionally, our findings that
environmental persistence is a driver of transmission of not only C. difficile networks but
genetically-identical strains, suggests that patients in our dataset with recurrent infections may
have resulted from contact with a consistently contaminated hospital environment.

Conclusion
C. difficile remains one of the most prevalent and damaging HAIs both globally and in the
US1,22,111. Efforts to mitigate the impact of CDI on vulnerable populations such as ICU patients
predominantly focus on the course of infection rather than the root cause of infection16,76,90,109.
Our approach of examining the mechanisms driving endemic rates of CDI is even more prudent
in a time of increasing antibiotic resistance. This study has yielded findings to further our clinical
and scientific understanding of how C. difficile spreads within the healthcare environment and
the drivers of transmission. I observed transmission clusters containing patients with clonally
related strains with unit overlap spanning as little as 1 week, to as much as 4 years apart.
Additionally, the data suggests that the unit overlap was not in the units in which the CDI was
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diagnosed. These results strongly suggest that the source of transmission is environmental
exposure to units visited earlier in the hospital admission prior to having a positive CDI test
result.
The standard protocol following a CDI diagnosis is cleaning and containment, which is
seemingly effective given that we did not observe patient overlap in the units where patients
tested positive. Consequently, this suggests that direct patient-to-patient transmission does not
play a major role in transmission, and that environmental persistence caused by ineffective
cleaning of units visited prior to diagnosis is driving in transmission. This study has provided
new data to inform evidence based infection control guidelines to reduce the incidence and
prevalence of CDI in the hospital environment.

Limitations
One limitation of this study was the potential for selection bias introduced by not collecting
samples from all patients. In the instance of ICU surveillance sampling, nurses were tasked with
collecting specimens from all patients admitted to an ICU, which I then transported back to our
laboratory for testing. There were two scenarios which may have caused an ICU patient to not be
sampled. The first possibility was random variation in sample collection caused by nursing
compliance with collecting a sample due to lack of study support or other reasons unrelated to
the subject. In this scenario missing samples may have caused random error which could have
biased incidence by indicating a lower value of the true level of asymptomatic prevalence.
However, considering the robust number of samples collected and screened dictated by a sample
size calculation, the magnitude of effect caused by missing samples would be low. Furthermore,
missing samples would not impact identifying cases or the transmission analysis given that

96

patients were tracked throughout their entire hospitalization, regardless of if they had a specimen
collected in the ICU.
The second possibility for missing samples from ICU patients and what can cause selection bias
was if the reason for not collecting a sample was also related to being an asymptomatic carrier.
This can bias associations in either direction depending on how the predictor impacts the chances
of sample collection. In the above example, our results would shift towards the null hypothesis
by reporting an artificially lower carrier rate due to lack of sampling. These impacts on internal
validity were addressed by using a sample size with a power >0.8, and a specific sample
selection strategy to ensure adequate representation among the sampled patients.
In the case of missing samples from positive CDI patients, all CDI positive test samples were
collected when possible. Missing positive CDI samples occurred if they had been discarded in
the CML before we could collect, CDI diagnostic testing in the CML depleted the entire sample,
or samples did not grow or sequencing during the laboratory analysis. These scenarios would be
caused by random error and would not bias associations in a specific direction.
Any potential possibility of confounding was derived from uncontrolled confounders, which as
previous epidemiological literature has indicated is not controllable189.
Laboratory error during the asymptomatic screening procedure was addressed by randomizing
the order of samples throughout the experimental process to avoid batch effects. Lastly, in the
second half of the first year of the study there was a change in the diagnostic testing
methodology used in the CML which may have had an impact on the case cohort. However, both
methodologies are considered high-sensitivity and there were no observed changes in
transmission rates, therefore likely did not impact the study findings. Additionally, this did not
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affect the prevalence of the asymptomatic carrier rate, given I used ICU samples in the screening
and not diagnostic tests from the CML. The factors impacting lower microbial detection such as
bacterial load or microbial flora are unknown in relation to the new testing protocol and therefore
cannot be controlled for. I believe this measurement error had a very low magnitude of effect on
the overall results given that the longevity of the study provided a constant rate of CDI, and the
incidence of case patients remained an adequate sample size regardless of the new CML testing
procedure.
Overall, the possible limitations I identified were controlled to the best of my abilities, however
all research is subject to possible unknown outside influence. To overcome these limitations,
future studies are required to further identify predictors for CDI disease outcome, mechanisms of
transmission, and environmental persistence.

Future directions
In this study I observed an 8.0% rate of asymptomatic carriage and identified the presence of
carriers in the transmission clusters. Further study is needed to understand the directionality of
carriers involved in the clusters to determine if they acted as drivers of environmental
contamination or were on the receiving side of transmission. Additionally, the patients identified
as carriers had no history of CDI and did not later develop symptoms during the study period.
Further study is needed to understand why these patients had the same strain of C. difficile and
similar comorbidities but did not develop symptomatic infection.
Genomic sequencing technology was the critical method used in this study, and is a valuable tool
in not only outbreak tracking but understanding how diseases move through an environment and
population. Genomic technology provides a level of precision surveillance without which we
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would be oblivious to what is a coincidental case of same strain infections versus a true outbreak.
This technology allowed us to identify environmental persistence as the driver of transmission
within the data. Using genomics also enabled observation of transmission clusters that spanned
multiple units, patients, and years, which would otherwise have remained undetected. We were
then able to merge this transmission cluster data with patient admission history and identify the
presence of reservoir units. The methods utilized in this study should be applied to other hospital
acquired infections to increase our understanding of persistence in the presence of effective
containment and cleaning protocols. The future of infection control must focus on expanding
strategies beyond defensive measures in response to infection, and must apply proactive efforts
to mitigate the root of transmission. With the implementation of evidence based strategies we
can work towards reducing the burden of C. difficile and ultimately eliminate the associated
morbidity and mortality caused by HAI.
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